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The interaction of the EGFR–PI3-K/AKT pathway with the tumour 
microenvironment in head and neck cancer  
 
 
Head and neck squamous cell carcinoma  
Head and neck squamous cell carcinoma (HNSCC) belongs to the ten most common 
carcinomas with an incidence of 800.000 new cases annually worldwide and 2,400 
cases annually in The Netherlands. HNSCCs arise from the mucosa of the upper 
aerodigestive tract and include squamous cell carcinomas of the larynx, pharynx, and 
the oral cavity [1]. Less frequent tumour entities are tumours of the nasal cavity, 
paranasal sinuses or salivary gland, and sarcomas. The most common risk factors are 
alcohol and tobacco abuse, but infection with the Human-Papilloma virus (HPV) has 
recently been identified as a cause of oropharyngeal cancer in relatively young, non-
smoking patients [2]. Successful treatment depends mainly on the stage of the tumour 
at presentation. Early diagnosis and treatment offers patients the best change of 
complete recovery. As patients often experience vague complaints such as throat ache 
or dysphagia, many of them present with advanced local disease already with lymph 
node metastases [3]. Due to a preference for organ preservation, the principal 
treatment modality is radiotherapy; which is effective in early-stage tumours, but less 
effective for advanced tumours and only palliative in metastatic disease [4]. 
Resistance of tumour cells to radiation is complex and many intrinsic and extrinsic 
factors are involved. In recent years, research has focussed on optimizing treatment 
modalities such as accelerated radiation schedules and combination therapies like 
chemoradiation or molecular targeting agents in addition to radiation to increase 
survival rates [5,6]. Although only for a selection of patients, (15% at best) there is 
benefit from these combination therapies, all patients experience the increased side 
effects. Therefore, it is mandatory to be able to select those patients who are most 
likely to profit prior to treatment.  
 
Radioresistance mechanisms 
The tumour microenvironment plays a key role in resistance to radiotherapy. How 
well tumour cells respond to radiotherapy does not only depend on their ability to 
repair the radiation-induced DNA-damage, but also on their proliferative response 
capacity induced by and during radiotherapy. Furthermore, tumour cell hypoxia 
induces radioresistance, and in addition, it is also known to promote genetic 
instability, leading to a more aggressive phenotype with increased tumour cell 
invasiveness and metastasis, resulting in worse clinical outcome.  
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Intrinsic radiosensitivity  
Although HNSCCs are mostly intermediate sensitive for radiotherapy, there are broad 
inter-tumour variations. There exist significant patient-to-patient differences between 
tumours of the same clinical stage and histology in response to radiation treatment. 
This variation can be explained by differences in intrinsic or microenvironmental 
factors. Intrinsic radiosensitivity is influenced by factors as the ability to repair 
radiation-induced DNA single- and double-stranded breaks (DSB). DSBs are 
potentially lethal DNA lesions and targeting signalling pathways involved in the DNA 
repair response sensitises tumour cells to ionising radiation. Combining radiotherapy 
with blockade of these signalling pathways, thereby interfering with DNA DSB repair, 
has resulted in improved local control compared to radiotherapy alone [7].    
 
Enhanced proliferation 
Between treatment intervals, cells are triggered to repopulate more effectively. This 
enhanced tumour cell proliferation is an important cause of treatment failure [8,9]. 
Accelerating radiation treatment schedules have been shown to be effective to 
counteract accelerated proliferation. By delivering more than one fraction per day, the 
overall treatment time can be reduced whilst maintaining the same total radiation 
dose. With acceptable acute toxicity levels, shortening the overall treatment time has 
been demonstrated to contribute to a significant benefit in loco-regional control and 
disease-specific survival in head and neck cancer patients [10,11]. Tumour cell 
proliferation depends on multiple factors such as differentiation grade and 
microenvironmental elements such as oxygen and nutrient availability. 
 
Tumour cell hypoxia 
Hypoxic regions are found in almost all solid tumours. Two major forms of hypoxia 
can be distinguished: chronic (diffusion-limited) and acute (perfusion-limited) 
hypoxia, although regions of intermediate hypoxia within a tumour can be found 
(Figure 1). Due to this variable degree of hypoxia, a cut-off value to distinguish 
normoxic from hypoxic tumour cells does not exist. In most experiments, values below 
10 mm Hg have been defined as hypoxic areas although radioresistance may already 
occur below 25-30 mm Hg [12]. Both forms of hypoxia can co-exist within the same 
tumour with large differences between tumours regarding the amount of hypoxia and 
the relative contribution of acute versus chronic hypoxia. Acute hypoxia is often 
transient and due to a chaotic network of blood vessels with leaky vessels, shunts and 
other structural and functional abnormalities. Chronic hypoxia is caused by tumour 
growth thereby increasing the distance of tumour cells to the nearest blood vessels, 
leaving cells deprived of oxygen and nutrients [13]. There are many studies linking 
tumour cell hypoxia to the prognosis of head and neck cancer patients and outcome 
after radiotherapy [14,15]. Because of the “oxygen enhancement ratio (OER)”, hypoxic 
General introduction and outline of this thesis 
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cells are approximately three-fold more radioresistant than are normoxic cells 
[16,17]. Directly, oxygen is essential for the efficacy of radiation-induced DNA damage. 
Indirectly, hypoxia can lead to activation of hypoxia-induced proteins and genes 
responsible for tumour progression via various mechanisms [18]. These alterations 
may help tumour cells to become less dependent of oxygen for survival or help cells to 
escape to a more favourable environment, for example by the transformation of cells 
from an epithelial to a more mesenchymal phenotype (EMT) [19]. This leads to more 
aggressive tumour cells that are able to spread, forming regional and distant 
metastases and ultimately negatively affecting the prognosis for the patient.  
 
 
 
Figure 1. Acute & chronic hypoxia. Acute hypoxia is due to occluded blood vessels while chronic 
hypoxia is caused by increased distance of tumour cells to the nearest blood vessels. Hypoxia 
staining by pimonidazole (green), perfusion (red) of blood vessels (blue).  
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Metastases formation  
Metastasis formation not only involves EMT, but also the detachment from the 
primary tumour site and escape of single cells into the blood or lymph vessels 
followed by reattachment, transition back to the epithelial state and angiogenesis are 
required to form a secondary tumour [20,21]. During the first step, EMT, the 
expression of epithelial markers (for example E-cadherin) is suppressed and the 
expression of mesenchymal markers (vimentin) is enhanced. Regional and distant 
metastases have a major impact on prognosis and it is therefore of great importance 
to understand the mechanisms to be able to explore strategies that interfere early in 
this process.  
 
Epidermal Growth Factor Receptor  
The Epidermal Growth Factor Receptor (EGFR) is a transmembrane protein with 
intrinsic tyrosine kinase activity and commonly overexpressed in most epithelial 
cancers in particular HNSCC [22]. Overexpression correlates with resistance of 
tumour cells against radiotherapy and poor prognosis [23]. Ligand binding to EGFR, 
for example by EGF, or activation by ionizing radiation [24,25] induces conformational 
changes leading to receptor homo- or heterodimerization at the plasma membrane 
with one of its family members, ErbB2 (HER2), ErbB3 or ErbB4. As Figure 2 shows, 
activation of EGFR causes autophosphorylation (pEGFR) resulting in receptor 
internalisation and stimulation of many signalling pathways including RAS-mitogen-
activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK), 
phosphatidylinositol-3-kinase-AKT (PI3-K/AKT), signal transducers and activators of 
transcription (STAT) and the phospholipase C gamma (PLC- γ) pathways [7,24,26]. All 
these pathways are responsible for regulation of tumour cell proliferation, DNA-
damage repair, migration, angiogenesis, and tumour cell survival. The main focus of 
this thesis will be the activation of the PI3-K/AKT pathway. 
 
PI3-K/AKT pathway 
EGFR can lead to activation of the protein AKT by phosphorylation of Thr308 and 
Ser473 at the cell membrane via activation of PI3K. Phosphorylated AKT (pAKT) then 
translocates to the cytoplasm and nucleus leading to transcription of genes 
responsible for tumour progression, such as cellular proliferation and DNA-damage 
repair. Also genes involved in the cellular response to hypoxia, for example hypoxia-
inducible factor1α (HIF-1α) and vascular endothelial growth factor (VEGF) are, at 
least partly, controlled by pAKT. Besides activation through EGFR, the PI3-K/AKT 
pathway can be activated by several other mechanisms. These include activation 
through other receptor tyrosine kinases (RTKs), mutations in oncogenes upstream 
such as ras, loss of Phosphatase and tensin homolog deleted on chromosome 10 
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(PTEN) [27], or amplifications or mutations of the gene pik3ca, encoding the catalytic 
subunit of PI3K, or AKT itself [28,29]. 
 
The EGFR-PI3-K/AKT pathway is relevant for radiation response since it regulates a 
variety of cellular functions, including proliferation rate, DNA-repair and metastasis 
formation. In addition, a feedback between hypoxia and EGFR activation exists, 
making this pathway a key element in treatment responsiveness and therapeutic 
targeting in head and neck cancer.  
 
 
 
Figure 2. Downstream signalling pathways of the Epidermal Growth Factor Receptor (EGFR). 
Scheme only denotes a simplified representation.  
 
 
Prognostic and predictive value of EGFR-PI3-K/AKT signalling 
Several investigators have explored the prognostic role of EGFR in solid tumours. 
Mostly, they found a strong correlation between high EGFR expression and poor 
clinical outcome and resistance to radiotherapy [23,30]. EGFR activation can lead to 
enhanced proliferation during radiotherapy. Patients with high EGFR levels showed 
increased locoregional control rates after treatment with accelerated radiotherapy 
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compared to conventional radiotherapy schedules, while there was no benefit for 
those with low EGFR expression [31,32]. Thus, EGFR expression in HNSCC is a 
predictive factor for a benefit from accelerated radiation treatment. Intensive 
research during the last decade with focus on EGFR inhibition has resulted in a 
randomised clinical trial in patients with advanced head and neck cancer reporting an 
improved loco-regional control and survival when radiotherapy is combined with 
cetuximab, a monoclonal antibody against the outer part of the EGF receptor [6]. 
Unfortunately, these improvements are modest whereas all patients experience 
increased toxicity to some extent. Besides this, although EGFR expression is an 
important prognostic marker, it does not seem to predict treatment response to anti-
EGFR therapy. A possible explanation is that overexpression of EGFR in tumour cells 
does not necessarily implicate phosphorylation of the receptor and activation of 
downstream pathways; cells have to be dependent on EGFR signalling for their 
survival in order to respond to EGFR inhibition.  
 
Next to the prognostic value of EGFR, pAKT was also found to be an independent 
significant factor for patient outcome. Although most studies correlate high pAKT 
expression to poor outcome [33-37] there are also studies linking high pAKT levels to 
better survival [38-41] or reduced migration with variable results in different tumour 
types [42-45]. These contradictory results point out the need for tumour-type specific 
research to unravel this complex signalling cascade.   
 
The tumour microenvironment plays an important role in signalling of EGFR and 
activation of AKT. Not only do not all EGFR expressing cells activate AKT signalling, it 
is also shown that in hypoxic areas within tumours of the head and neck pAKT is 
present without EGFR expression. Cells that retain their potential to activate survival 
pathways in harsh circumstances like hypoxia represent an important subpopulation 
of tumour cells that are responsible for treatment failure [46]. Besides 
immunohistochemically staining for EGFR and pAKT expression, tumour cell hypoxia 
and proliferation can be assessed in patient biopsies prior to treatment. Endogenous 
markers such as Ki-67 and proliferating cell nuclear antigen (PCNA) or exogenous 
markers like S-phase specific thymidine analogues bromodeoxyuridine (BrdUrd) and 
iododeoxyuridine (IdUrd) are available to indicate the amount of proliferating tumour 
cells. In several studies the relationship between these markers and response to 
radiotherapy was assessed, with inconclusive results about their predictive value 
[31,47,48]. This suggests that the proliferative response of tumours during treatment 
is probably independent of baseline proliferation. Hypoxic areas can be stained by 
intravenously administered bio-reductive chemical markers such as the 
nitromidazoles pimonidazole or EF5 [49]. These markers have the advantage that 
they only metabolise in active cells and, therefore, necrotic tissue does not generate a 
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signal. Endogenous hypoxia-related markers are involved in the tumour cell response 
to hypoxia, but also to other stress-related aspects like intratumour pH. Proteins that 
show the most promising results as potential hypoxic markers are hypoxia-inducible 
factor 1α (HIF-1α), carbonic anhydrase IX (CAIX) and glucose transporters 1 and 3 
(GLUT) [13,50]. 
 
Counteracting radioresistance in head and neck cancer 
To overcome enhanced tumour cell proliferation during treatment and tumour cell 
hypoxia numerous strategies have been clinically tested. Different studies show that 
accelerated tumour cell proliferation can be counteracted by accelerated radiotherapy 
[10,11], while tumour hypoxia can be reduced using a hypoxia-modifying treatment 
combined with radiotherapy [51,52]. These latter treatments vary from hyperbaric 
oxygen and carbogen breathing to hypoxic cell sensitizers, using nitroimidazoles, and 
hypoxic cytotoxins, to destroy hypoxic cells [53]. A recently published meta-analysis 
including 32 randomized clinical trials demonstrated that there is a significant 
beneficial effect of hypoxic modification if combined with radiotherapy [54]. 
A strategy that integrates both accelerated radiotherapy and hypoxia modification is 
Accelerated Radiotherapy with CarbOgen and Nicotinamide (ARCON) [16]. Breathing 
carbogen, a hyperoxic gas (98% O2; 2% CO2), during accelerated radiation treatment 
will sensitize tumour cells through reduction of diffusion-limited hypoxia. The orally 
administered vasodilating compound nicotinamide reduces perfusion-limited hypoxia 
by preventing intermittent closure of tumour blood vessels. A phase II study involving 
215 patients with advanced head and neck cancer showed high local and regional 
control rates, in particular for oropharynx and larynx tumours [55]. Results from a 
subsequent phase III study involving 345 patients with laryngeal carcinoma showed 
higher regional control rates without an increase in toxicity [56]. Results from a side 
study using the exogenous hypoxia marker pimonidazole revealed that this increase 
was only significant in the more hypoxic tumours. Patients with hypoxia higher than 
median levels receiving ARCON had higher regional control and disease-free survival 
rates compared to the standard AR treatment. Patients with well-oxygenated tumours 
did not benefit from the addition of carbogen and nicotinimide to radiotherapy. This 
illustrates that identification of microenvironmental characteristics, in this example 
the amount of hypoxia, may allow a better selection of patients for different treatment 
methods, with the ultimate aim to provide the best quality of life for individual cancer 
patients.  
Another way to try to predict patients from a beneficial effect of ARCON treatment is 
possibly via the activation of the EGFR-PI3-K/AKT pathway, which is associated with 
proliferation and hypoxia response. This signalling pathway may influence the 
therapeutic effect and may therefore be a powerful predictor for treatment with 
ARCON.  
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Outline of this thesis 
The central aim of the present thesis is to investigate the activation of the EGFR-PI3-
K/AKT pathway in biopsies of head and neck squamous cell carcinoma patients and 
its implication for radiation resistance. Besides their potential prognostic or 
predictive value, we evaluated their expression related to microenvironmental factors, 
like the presence of hypoxia or vasculature.  
 
Chapter 2 gives an overview of the role of EGFR in head and neck cancer, its 
interaction with the tumour microenvironment and their involvement in 
radioresistance. This chapter illustrates that both irradiation and hypoxia can 
influence EGFR activation and we therefore hypothesized that EGFR could modulate 
the response to accelerated radiotherapy and hypoxia modification. Chapter 3 
describes the findings on the predictive value of EGFR expression in 272 laryngeal 
cancer patients on the outcome of hypoxia modification in addition to accelerated 
radiotherapy (ARCON). 
In chapter 4, the relative contribution of activated EGFR on the activation of 
the PI3-K/AKT pathway was examined in a cohort of 58 patients. We investigated 
expression levels of pEGFR and pAKT and correlated these to patient outcome. Also, 
the relationship between pEGFR, pAKT, vessels, and hypoxia was assessed. We 
discovered a distinct relationship of pAKT expression in the primary tumour of HNSCC 
patients and lymph node metastases. Our hypothesis was that this counterintuitive 
correlation between pAKT and an increased metastasic risk might be due to epithelial-
mesenchymal transition (EMT). This led us to explore the association of markers; i.e. 
E-cadherin and vimentin, involved in EMT in this patient group.  
Chapter 5 describes the association between EGFR and pAKT and E-cadherin 
and vimentin expression. Low E-cadherin and high vimentin expression lead to 
reduced cell-cell contact and higher possibility of cells to migrate and form 
metastases.  
There is an increasing number of early clinical trials exploiting the inhibition of 
specific target proteins and genes in addition to radiotherapy. One such inhibitor is 
MK-2206, an allosteric inhibitor of pAKT. It alters the shape of AKT so that ATP 
binding at the phosporylation sites Th308 and Ser473 is prevented. Due to our 
previous finding that pAKT expression seemed to be involved in increased regional 
and distant metastatic risk we performed experiments to investigate the effect of 
pAKT inhibition on EMT in laryngeal cancer cells, which are described in chapter 6.  
 
Chapter 7 provides a general discussion including future perspectives. A 
summary of this work is given in chapters 8 (Dutch) and 9 (English).  
General introduction and outline of this thesis 
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Abstract 
Treatment failure through radioresistance of tumours is associated with activation of 
the epidermal growth factor receptor (EGFR). Tumour cell proliferation, DNA-repair, 
hypoxia and metastases-formation are four mechanisms in which EGFR signalling has 
an important role. In clinical trials, a correlation has been demonstrated between high 
EGFR expression in tumours and poor outcome after radiotherapy. Inhibition of EGFR 
signalling pathways improves the effectiveness of radiotherapy of head and neck 
cancers by overcoming these main mechanisms of radioresistance. The fact that only a 
minority of the patients respond to EGFR inhibitors reflects the complexity of 
interactions between EGFR-dependent signalling pathways and the tumour 
microenvironment. Furthermore, many components of the microenvironment are 
potential targets for therapeutic interventions. Characterisation of the interaction of 
EGFR signalling and the tumour microenvironment is therefore necessary to improve 
the effectiveness of combined modality treatment with radiotherapy and targeted 
agents. Here, the current status of knowledge is reviewed and directions for future 
research are discussed. 
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Introduction 
The epidermal growth factor receptor (EGFR) attenuates the efficacy of radiotherapy 
in tumour cell killing through its association with enhanced proliferation, DNA-repair 
and hypoxia. Intracellular signalling of EGFR occurs via phosphorylation cascades in 
different pathways in which protein kinase B (PKB/AKT) is a key-regulating factor. 
However, immunohistochemical staining of EGFR and phosphorylated (p)AKT shows 
that EGFR-independent activation of AKT also occurs, predominantly in hypoxic areas 
[1,2]. This observation suggests that activation of specific proteins in the important 
signalling cascades may also depend on microenvironmental characteristics, such as 
tumour oxygenation status. Vice versa, manipulation of EGFR affects the tumour cells 
[1]. Understanding the microenvironmental conditions that influence important 
signalling pathways in tumours insensitive to particular treatment regimens can 
improve selection of patients for individualized treatment options. In this review we 
will discuss the interactions between the EGFR signalling cascade and the tumour 
microenvironment (Figure 1), using mainly preclinical data as well as the available, 
albeit limited information from clinical studies.  
 
Tumour microenvironment  
Our current conception of a malignant tumour is that of a complex structure 
containing not only cancer cells but also a variety of normal cell types that intimately 
interact with a microenvironment that is characterised by both temporal and spatial 
heterogeneity. It has become clear that this tumour microenvironment is important 
during early cancer development and progression, and is also of influence on the 
response of tumours to radiation [3,4]. Elements that make up the tumour 
microenvironment include endothelial cells of the blood and lymphatic vessels, 
fibroblasts, infiltrating cells of the immune system and the tumour extracellular 
matrix (ECM) [5]. Availability of oxygen and nutrients depends on the functionality of 
the vascular bed and affects the metabolic state of tumour and stromal cells. An 
imbalance between oxygen and glucose supply and consumption will result in hypoxia 
and acidification. Within the tumour microenvironment, hypoxia is relevant in almost 
all solid tumours. Reduced oxygen supply can be lethal for some cells, but others are 
able to survive under even severe or prolonged hypoxic conditions. Hypoxia-induced 
cell signalling promotes tumour growth, migration and survival. The development of 
new vasculature within a tumour involves the formation of new vessels from 
endothelial cells (vasculogenesis) in addition to sprouting (angiogenesis) of new 
vessels from existing ones [6]. New tumour blood vessels, prerequisite for tumour 
progression and metastasis formation, the result of interplay between pro- and anti-
angiogenic factors, is predominantly regulated through transcription of the hypoxia-
inducible-factor (HIF)-1 complex. The pro-angiogenic factor VEGF is a crucial gene 
involved in angiogenesis that is strongly induced by hypoxia. Anti-angiogenic therapy, 
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for example by using anti-VEGF monoclonal antibodies such as bevacizumab, can 
result in a reduction of tumour vascularisation, but counter-intuitively also in 
normalisation of the aberrant tumour vasculature, thereby improving oxygenation 
and blood flow that could enhance the efficacy of radiation [7,8]. However, VEGF can 
also be upregulated in an oxygen-independent manner. Also, low extracellular pH 
causes stress-induced alteration of gene expression including the upregulation of 
VEGF in tumour cells in vitro. Tissue pH appears to regulate VEGF transcription 
through a different pathway independently of hypoxia, namely Ras-ERK1/2 instead of 
HIF mediated [8].  
 
 
 
 
Figure 1. Interaction between EGFR signalling, radiotherapy and the tumour microenvironment 
leading to radioresistance. Different aspects of the tumour microenvironment can activate 
signalling pathways, via EGFR or directly and EGFR-independent. Activation of downstream 
proteins/genes affects the tumour microenvironment, e.g. via angiogenic factors and effects on 
the extracellular matrix. Both tumour microenvironmental factors as well as EGFR signalling 
can lead to more radioresistant tumours.  
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Cancer-associated fibroblasts can influence different aspects of tumour cell behaviour 
such as growth and migration trough release of growth factors and chemokines. 
Various cells of the immune system found in solid tumours play an important role in 
modulating tumour growth. Macrophages form a major inflammatory population in 
most cancers but other components of the inflammatory infiltrate also module tumour 
behaviour, having pro- and anti-tumour functions [5].  
Exchange of information between tumour cells can occur from the ECM to tumour 
cells directly, via mechanical forces, or can be mediated by ECM-associated growth 
factors [9]. The signals triggered by components of the ECM are not function-specific 
and depending on the local environment they can induce proliferation as well as the 
phenomen known as epithelial-mesenchymal transition (EMT). During this process 
tumour cells change from an epithelial morphology to a migratory and invasive, 
mesenchymal phenotype [10]. Growth factors, such as EGF, and stress stimuli like 
hypoxia, have been shown to induce EMT in vitro by inducing phosphorylation of E-
cadherin resulting in its degradation thereby linking growth factor receptor signalling 
to the induction of EMT [11]. 
 
Epidermal growth factor receptor and downstream signalling pathways 
EGFR is a transmembrane protein with intrinsic tyrosine kinase activity that is 
overexpressed in most epithelial cancers, e.g. in over 80% of head and neck squamous 
cell carcinomas (HNSCC) [12,13]. Overexpression could lead to resistance of tumour 
cells against radiation as demonstrated by in vivo studies [14-16] and is associated 
with poor prognosis in HNSCC [13]. (p)EGFR and HER2 expression are mostly 
determined by intrinsic features of the tumour cell, while the activation of 
downstream kinases is highly influenced by the tumour microenvironment [17]. 
Ligand binding to EGFR induces conformational changes leading to receptor homo- or 
heterodimerization at the plasma membrane with one of its family members, ErbB2 
(HER2), ErbB3 or ErbB4. This causes autophosporylation, subsequent receptor 
internalisation and stimulation of multiple signalling pathways including ras-mitogen-
activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK), 
phosphatidylinositol-3-kinase-AKT (PI3-K/AKT)), signal transducers and activators of 
transcription (STAT) and the phospholipase C gamma (PLC- γ) pathways [3,18,19]. 
These pathways all share that they counteract radiation efficacy being involved in 
proliferation, migration, apoptosis and angiogenesis. Of note is that, besides through 
ligand binding, EGFR can also be activated by ionizing radiation itself, again leading to 
radioresistance [18,20-22]. EGFR tyrosine kinase inhibition with erlotinib or gefitinib 
improves progression-free survival in advanced non-small cell lung cancer (NSCLC) 
with EGFR mutations [23]. In preclinical studies EGFR-expression was needed for 
C225-response, but this was not sufficient to predict response to C225 plus 
radiotherapy. Evaluation of the microenvironment revealed that basal expression of 
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additional growth factor receptors and effects on proliferation, correlated to a certain 
extend with response to combined C225-radiotherapy [24]. Combining radiotherapy 
with blockage of EGFR by the chimeric (mouse/human) monoclonal antibody 
cetuximab, has resulted in improved locoregional control and survival for patients 
with HNSCC [25] demonstrating that EGFR is an clinically relevant target for 
molecular therapies in addition to radiation. 
 
A key protein activated through EGFR is AKT that can be phosphorylated at Thr308 
and Ser473 at the cell membrane after activation of PI3-K. pAKT then translocates to 
the cytoplasm and nucleus where it can activate or deactivate a myriad of substrates 
via its kinase activity or via transcription of genes responsible for tumour progression. 
Although most studies correlate high pAKT expression to poor local control [26,27], 
there are also studies linking high pAKT to better survival or reduced migration 
[2,28]. This suggests that the concept of EGFR induced AKT activation leading to 
treatment resistance and poor outcome is a simplification of a complex interaction 
between the EGFR signalling network and the tumour microenvironment. 
Importantly, it is shown that hypoxia can induce cellular changes and in hypoxic areas 
of HNSCC activated AKT has been observed in absence of EGFR expression (Figure 2). 
Immunohistochemical staining for EGFR and pAKT in biopsies of patients with HNSCC 
reveals a lack of association: tumour cells positive for EGFR were found negative for 
pAKT and vice-versa (Figure 3). Although a better correlation between activated EGFR 
(pEGFR) and pAKT existed, there were still tumour cells present with pAKT but no 
pEGFR [2]. A possible explanation is that AKT can be activated by different members 
of the ErbB family and other type of receptors like VEGFR. This is supported by the 
observation that blocking VEGFR-2 caused a suppression of pAKT [29]. Also, these 
observations suggest that the tumour microenvironment may stimulate activation of 
AKT in an EGFR-independent manner and is likely to be involved in the other EGFR-
driven signalling pathways as well.  
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Figure 2. Immunohistochemial staining of whole consecutive laryngeal tumour sections shows 
that pAKT (green) expression (B) occurs predominantly in hypoxic areas stained with 
pimonidazole (green; A). Red is EGFR expression, mostly seen in normoxic areas closer to 
tumour blood vessels (white). 200X magnification. Scalebars represent 100 µm. 
 
Figure 3. Mismatch of EGFR (red) and pAKT (green) in tumour sections of a laryngeal carcinoma 
(200X magnification). A Tumour section with EGFR expression present but no activated AKT 
(white arrow) and tumour cells with EGFR-independent pAKT expression (yellow arrow). 
White is tumour vasculature (stained with PAL-E). Scalebar represents 100 µm. 
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Tumour microenvironmental factors and radioresistance  
Not only do tumours from different origins respond differently to radiotherapy, also 
tumours with similar pathology show broad variations in response. Resistance of 
cancer cells to radiation is complex and many intrinsic and extrinsic factors are 
involved. Activation of EGFR signalling pathways can influence various cellular 
functions that are involved in the major mechanisms leading to radioresistance 
including tumour cell proliferation, DNA-repair and hypoxia. Activation of EGFR is 
also involved in a fourth mechanisms leading to radioresistance of tumours namely 
the escape of tumour cells from local therapy by radiation through the formation of 
metastases. 
 
Tumour cell proliferation 
The accelerated proliferation rate of tumour cells during radiotherapy is one reason 
for locoregional failure [30]. A number of clinical trials have confirmed that 
shortening the overall treatment time leads to increased tumour control probability 
by reducing the possibility of tumour cells to enhance repopulation between 
radiotherapy fractions [31]. This accelerated proliferation rate can be a result of 
activation of EGFR in response to ionizing radiation and an explanation why tumours 
with high EGFR expression have a worse prognosis [13]. Two clinical studies have 
indeed confirmed that accelerated radiotherapy, either moderate acceleration with 6 
fractions per week over 5.5 weeks or accelerated hyperfractionation with 3 fractions a 
day, and a total treatment time of 12 consecutive days, results in better locoregional 
control when EGFR was overexpressed, but not in tumours with low EGFR expression 
[30,32]. This suggests that EGFR-related signalling is involved in the proliferative 
response to radiotherapy thereby enhancing tumour survival probabilities. Preclinical 
data confirm that radiation-induced activation of EGFR represents a critical step in the 
activation this mechanism [33]. Large-scale studies with fractionated irradiation in 
xenografted FaDu (HNSCC) tumours demonstrated that after 3-4 weeks of 
fractionated radiotherapy an enhancement of repopulation occurs. At the same time 
an upregulation of EGFR expression was observed, indicating that EGFR is involved in 
this response [34]. Inhibition of EGFR through cetuximab [35] or tyrosine-kinase 
inhibitors such as erlotinib [15] was found to reduce tumour cell repopulation. EGFR 
inhibition with cetuximab during fractionated radiotherapy reduced tumour cell 
repopulation and improved local control in FaDu tumours [35] but also leads to a 
change in spatial distribution of EGFR favouring the membranous expression [36]. 
Erlotinib can inhibit radiation-induced activation of EGFR thereby reducing its 
proliferative signalling capacity. Both agents have demonstrated to lower the 
percentage of human tumour cells in the more radioresistant S-phase fraction and 
induce an accumulation of cells in the more radiosensitive cell cycle phases [37]. 
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Consistent with these findings, Krause et al. observed a significantly lower S-phase 
fraction measured by BrdU labelling after treatment with a tyrosine kinase inhibitor in 
FaDu tumours compared to untreated tumour. However, this reduced proliferation 
did not lead to improved local tumour control after radiation [38]. Additionally, 
Gurtner et al showed that in a panel of HNSCC models erlotinib as well as cetuximab 
lead to tumour growth delay but only simultaneous application of cetuximab during 
fractionated irradiation improved local control, while erlotinib did not enhance the 
radiotherapy effect [39], illustrating that different models of EGFR inhibition may lead 
to different ultimate treatment results.  
 
DNA-repair 
Activation of the EGFR downstream pathways RAS and PI3-K/AKT have been found to 
increase the resistance of tumour cells to agents that cause DNA damage [40]. DNA 
double strand breaks (DSB) are the most important DNA lesions leading to cell kill 
after radiotherapy. Tumour cells can repair DSBs through non-homologous end-
joining (NHEJ) and homologous recombination (HR). NHEJ is the major process 
responsible for survival of cells exposed to ionizing radiation, making this type of 
repair probably most influencial for treatment outcome. An important molecular 
complex involved in this process is the DNA-dependent protein kinase catalytic 
subunit (DNA-PKcs), which is known to reside primarily in the nucleus. An interaction 
between nuclear EGFR and DNA-PKcs has been described suggesting a crucial role of 
nuclear EGFR for regulation of DNA repair after radiation [41]. Activated EGFR can be 
internalized and translocated to the nucleus and irradiation-induced nuclear EGFR 
can stimulate the formation of the nuclear EGFR/DNA-PKcs complex [42].  Selective 
inhibition of these pathways was found effective in reducing tumour cell survival. For 
example, cetuximab blocked radiation-induced nuclear translocation of EGFR and was 
associated with inhibition of radiation-induced activation of DNA-PKcs in a human 
bronchial carcinoma cell line [42]. Combined treatment of radiation and cetuximab 
resulted in a redistribution of DNA-PKcs from the nucleus to the cytoplasm. The 
reduction of DNA-PKcs in the nucleus leads to impeded NHEJ, essential for DNA-repair 
and survival. This might be a potential mechanism of the combined modality approach 
whereby the repair of DNA-DSBs after radiotherapy is impaired by cetuximab [37]. 
Blockage of radiation-induced DNA-PKcs activation by EGFR, PI3-K or AKT inhibition 
as well as through knockdown of AKT1 by siRNA indicates the requirement of the 
EGFR-PI3-K/AKT pathway for regulation of DNA-DSB repair after exposure to ionizing 
radiation [43]. Selective EGFR inhibition by gefitinib increased radiosensitivity of 
stem-like gliomaspheres by reducing DNA-PKcs expression, accompanied by reduced 
repair of radiation-induced DNA DSBs [44]. These studies suggest that EGFR mediated 
repair of DNA damage might play a prominent role in the mechanism of 
radioresistance. Further preclinical in vivo and clinical research is required to 
30 
 
determine to what extent this is a tumour type specific mechanism and to identify 
predictors of response to EGFR- or downstream PI3-K/AKT-targeted DNA-repair 
inhibitor. 
In conflict with other studies, a novel finding showed that cetuximab as well as 
irradiation can promote EGFR translocation to the nucleus. Cetuximab treatment 
resulted in phosphorylation of the EGFRy845 site leading to an increased translocation 
to the nucleus of HNSCC tumour cells. This process can be inhibited by dasatinib, an 
inhibitor of several kinases including SRC family kinases (SFKs), which are suggested 
to be necessary for the phosphorylation of the EGFRy845 site and cetuximab-induced 
EGFR translocation to the nucleus [45]. Whether this cetuximab-induced nuclear 
EGFR is able to activate target genes to the same extend as ligand binding or radiation 
does is still unclear.  
 
Hypoxia 
The consequences of tumour cell hypoxia for treatment and patient outcome have 
been well established [46,47]. Hypoxia is associated with treatment failure as hypoxic 
tumour cells are significantly more resistant to radiation than normoxic cells. 
Although hypoxia is considered a limiting factor for tumour growth it is a stimulus for 
invasion and metastasis formation [5]. To adapt to hypoxic conditions, cells can 
respond by activating hypoxia-inducible genes or pro-survival signalling pathways, 
directly or indirectly through induction of the transcription factor hypoxia-inducible-
factor (HIF)-1 complex [48,49]. HIF-1 modulates the expression of genes involved in 
cell survival, angiogenesis and migration [10,50,51]. After HIF activation by hypoxia, 
processes are induced in cells to adapt to low oxygen levels, including metabolic 
changes and angiogenesis. Various treatment strategies have been developed to 
address the hypoxia problem [52,53]. The hypoxic sensitizer nimorazole has been 
shown to improve locoregional control in HNSCC when applied in conjunction with 
radiotherapy [54]. Also, ARCON (accelerated radiotherapy with carbogen breathing 
(98% O2, 2% CO2) and nicotinamide) a treatment method that aims to counteract both 
tumour cell repopulation and hypoxic radioresistance has demonstrated benefit for 
hypoxic laryngeal carcinomas [55,56]. A meta-analysis demonstrated that there is a 
level 1a evidence in favour of adding hypoxic modification to radiotherapy in HNSCC 
[53].   
In biopsies of breast cancer patients, expression of HIF-1α is associated with EGFR 
expression [57]. A feedback loop between hypoxia-induced upregulation of HIF-1α 
and EGFR provides sustained signalling when oxygenation of tumour cells improves, 
even up to normoxic conditions. Preclinical research shows that activation of HIF is 
required for the up-regulation of EGFR protein levels in hypoxic cancer cells. 
Conversely, EGFR-driven PI3-K/AKT activation in breast cancer cells can also lead to 
increased levels of HIF-1α independently of hypoxia [58]. The exact mechanism by 
which PI3-K/AKT signalling mediates the induction of HIF is not clear yet and is not 
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confirmed in other tumour cell lines [59], suggesting that this phenomenon may be 
cell type specific. In cervix carcinoma and pheochromocytoma cells, hypoxia resulted 
in the induction of HIF-1α proteins with AKT activation present. However, after 
growth factor stimulation under normoxic conditions there was no induction of the 
HIF protein and/or its transcriptional activity although the treatment resulted in 
activation of the PI3-K/AKT pathway. These data suggest that merely the activation of 
this pathway may not be sufficient for the accumulation of the HIF-1α protein, at least 
not in all tumour types.  
Thus, interactions between the EGFR-PI3-K/AKT and HIF pathways vary with tumour 
type and oxygenation status. Furthermore, different effects can be measured at 
protein and mRNA levels. For example, blocking EGFR in HNSCC cells leads to 
decreased translation of HIF-1α protein under hypoxia, but inhibition does not 
completely eliminate HIF expression under hypoxic circumstances nor are the HIF-1α 
mRNA levels altered [60]. Pore et al. also found that nelvavir, a drug known to inhibit 
PI3-K/AKT signalling, decreases HIF-1α protein expression in HNSCC and lung cancer 
cells indicating that hypoxia-driven EGFR signalling might act via this downstream 
pathway in these tumour types [61]. HIF activation can also occur via radiation-
induced EGFR signalling. Recently, Lu et al. showed that cetuximab could inhibit 
radiation-induced HIF-1α upregulation in HNSCC [62]. This inhibitory effect of 
cetuximab was much weaker for hypoxia-induced HIF-1α than for radiation-induced 
HIF-1α expression supporting the mediator role of EGFR in the latter. In addition, a 
connection between EGFR and VEGF, a downstream target of HIF-1α exists and EGFR 
inhibition using erlotinib leads to downregulation of HIF-1α expression and decreased 
VEGF secretion [29]. Erlotinib improves tumour oxygenation via improved vascular 
perfusion but this decrease in hypoxia did not seem to have an effect in 
radiosensitivity in HNSCC xenografts and cells [63]. Gefitinib treatment reduced 
pimonidazole binding in A431 xenografts after 5 and 8 days of treatment showing that 
gefitinib reduces intratumoural hypoxia [64].  
These data indicate that activation of hypoxia-inducible genes is cell type specific, and 
that there is an intricate interaction between growth factor receptor activation and 
microenvironmental signalling. Tumour cell hypoxia can result in creating an optimal 
environment for tumour regrowth by activating hypoxia-induced genes leading to 
angiogenesis, while it also is associated with decreased radiation-induced DNA 
damage and a poorer response to radiotherapy making hypoxia a key element in the 
clinical outcome of patients [65]. Therefore, inhibition of EGFR in combination with 
hypoxia modification should be further explored as it might offer a powerful strategy 
for treatment of a number of cancer types.  
 
Experimental evidence has also provided a relationship between EGFR signalling and 
angiogenic proteins such as VEGF. Tumours often express high levels of VEGF leading 
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to an abnormal vasculature. Vascular normalization and an increase in tumour blood 
flow can be achieved by directly targeting VEGF or its receptor (VEGFR), with for 
example the anti-VEGFR monoclonal antibody bevacizumab. Also, EGFR inhibition 
with erlotinib in mice bearing SQ20B head and neck xenografts caused changes in 
vessel morphology, a decreased vascular permeability and an increase in tumour 
blood flow. This indicates that EGFR inhibition has an effect on vasculature resulting 
from a decrease in VEGF expression [63]. The combination of four weeks treatment 
with cetuximab and ZD6474, a potent inhibitor of VEGFR-2 tyrosine kinase with a 
significant anti-EGFR tyrosine kinase activity, showed a more significant growth 
inhibition in mice bearing colon or lung adenocarcinoma xenografts as compared to 
single agent treatment [29]. A normal tumour vasculature and improvement in 
tumour blood flow can lead to better drug delivery or increased tumour oxygenation, 
and, thereby, a better response to radiotherapy.  
 
Metastases formation  
The escape of tumour cells from the primary tumour to distant sites and subsequent 
formation of metastases is a fourth mechanism leading to treatment failure. During 
EMT, the loss of E-cadherin proteins leads to the disruption of stable adherent 
junctions. In addition, cells develop a more mesenchymal phenotype, e.g. increased 
expression of mesenchymal proteins like vimentin, and thereby more able to spread 
to secondary locations in the body. Increasing evidence indicates that EGFR signalling 
pathways are implicated in the regulation of proteins involved in EMT. In cervical as 
well as prostate cancer cells lines, EGF treatment significantly decreased the 
abundance of E-cadherin protein and upregulated vimentin expression [66,67]. Also, 
in surgical biopsies of cervical carcinomas EGFR overexpression was accompanied by 
decreased E-cadherin and increased vimentin expression seen by immunofluorescent 
staining [66].  
More evidence was provided by studies using EGFR inhibitors. An HNSCC tumour 
model in which cells dominantly express epithelial markers was found to be very 
sensitive to cetuximab, whereas those expressing mesenchymal markers revealed low 
sensitivity [68]. Although the exact interaction was not elucidated, this response to 
EGFR inhibition suggests that there is an association between EGFR pathways and 
EMT. However, this interaction between EGFR signalling and EMT seems to be tumour 
line specific. Combining cetuximab with irradiation induced EMT in the cetuximab-
sensitive cells while triggering the reverse mesenchymal-epithelial transition (MET) 
in the more mesenchymal cell line [68]. The idea is that cells that have undergone 
EMT become less dependent on EGFR signalling for cell proliferation and survival and 
are thus less responsive to EGFR inhibitors [69]. This also points towards a possibility 
of using EMT-related proteins as predictive markers for sensitivity to cetuximab. This 
hypothesis needs to be confirmed in tumours from patients either sensitive or 
resistant to EGFR inhibition but it clearly suggests a potential for individualised 
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treatment approaches employing EGFR-targeting or more aggressive anti-metastasis 
treatment based on EMT phenotype. 
Conversely, it has been shown that E-cadherin-mediated-cell-cell adhesion can trigger 
a ligand-independent activation of EGFR thereby regulating various signalling 
pathways such as MAPK and AKT [70,71]. Reddy et al. showed that activation of AKT 
and MAPK by E-cadherin mediated cell-cell adhesion in ovarian cancer cells is 
regulated by EGFR activation. However, no direct physical interaction between E-
cadherin and EGFR could be detected in the cells used, suggesting the existence of 
intermediate molecules [71]. In contrast, it was demonstrated that in oral squamous 
carcinoma cells E-cadherin can physically interact with and activate EGFR, leading to 
the activation of MAPK [70]. This interaction leads to EGFR-E-cadherin complex 
formation at cell-cell junctions and receptor oligomerization. Although the exact 
mechanism is unclear and needs to be verified, both studies show that E-cadherin may 
not only act as an adhesion molecule but also as an upstream regulator that triggers 
EGFR signalling pathways.  
Further, a relation between oxygenation status and EMT also exist. Hypoxia can down 
regulate E-cadherin and upregulate mesenchymal markers, indicating that hypoxia 
can contribute to metastases-formation through induction of EMT [72]. The 
morphological transformation induced by hypoxia in breast cancer and FaDu cells 
associated with EMT can be reversed after re-oxygenation or by repression of HIF-1α 
[72,73]. This finding at least partly explains the relation between tumour cell hypoxia, 
migration and ultimately metastasis formation.  
 
Conclusion  
There is strong evidence, both from preclinical and clinical studies that there is a 
positive correlation between the levels of EGFR found in tumour cells and resistance 
to radiation therapy and consequently treatment failure. EGFR signalling pathways 
are implicated in all major mechanisms of radioresistance. The tumour 
microenvironment has important influences on EGFR signalling. The fact that only a 
minority of the patients respond to EGFR inhibitors reflects the complexity of 
interactions between the EGFR-dependent signalling pathways and the tumour 
microenvironment. To improve the effectiveness of combined modality treatment 
with radiotherapy and targeted agents two strategies should be explored. One is 
patient selection based, not only on EGFR expression patterns, but also on 
microenvironmental characteristics to identify the tumour phenotypes that are most 
likely to benefit from the combined approach. Second is to combine radiotherapy, not 
only with EGFR signalling inhibition but also with treatments that counteract 
microenvironmental resistance mechanisms such as hypoxia, e.g. nimorazole, ARCON 
or angionesesis inhibition (VEGF inhibitors). Future preclinical and clinical studies 
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should focus on these multimodality approaches with mechanistic basis to bring 
cancer research forward. 
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Abstract 
Accelerated radiotherapy (AR) improves the poor prognosis associated with 
Epidermal Growth Factor Receptor (EGFR) overexpression frequently seen in head 
and neck carcinomas. Combining AR with carbogen and nicotinamide (ARCON) 
counteracts enhanced tumour cell proliferation- and hypoxia-related radioresistance. 
The purpose of this study was to investigate if EGFR expression levels are associated 
with response to ARCON in patients with carcinoma of the larynx.  
Patients (N=272) with advanced stage larynx carcinoma were randomized between 
AR alone and ARCON. Paraffin-embedded biopsies from these patients were processed 
for immunohistochemical staining of EGFR. EGFR fraction was quantitated by 
automated image analysis and related to clinical outcome.  
A large variation was observed in EGFR fraction between tumours with expression 
levels ranging from 0-0.93 (median fraction 0.4). No difference in 5-year locoregional 
control was found between low and high EGFR expressing tumours in the AR arm 
(69% versus 75%), which is in line with the established effect of AR in EGFR 
overexpressing tumours. There was, however, a significant association in the ARCON 
arm: patients with low EGFR levels had a better 5-year locoregional control (88% 
versus 72% p=0.02) and disease-specific survival (92% versus 77% p=0.01). ARCON 
improved locoregional control relative to AR only in patients with low EGFR 
expression (HR 0.34 p=0.009). 
In conclusion, only in tumours with a low EGFR fraction, adding hypoxia modification 
to AR has an additive beneficial effect on outcome. EGFR expression is a predictive 
biomarker for the selection of patients that will or will not respond to ARCON. 
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Introduction 
The Epidermal Growth Factor Receptor (EGFR) is a transmembrane receptor tyrosine 
kinase that plays a major role in regulating tumour cell proliferation and cell cycle 
progression [1,2]. EGFR is highly expressed in many solid cancers, including head and 
neck squamous cell carcinomas (HNSCC) [3] and is correlated with resistance to 
radiotherapy and decreased patient survival [4]. Ligand binding as well as ionizing 
radiation can phosphorylate EGFR [5] leading to activation of downstream cascades, 
like the PI3-K/AKT and the MAPK pathways [6]. These signalling pathways are 
responsible for enhanced proliferation, cell cycle progression and increased DNA-
repair leading to treatment failure [2,7,8]. 
How well tumour cells respond to radiotherapy depends on their proliferative 
response induced by and during treatment, their ability to repair the radiation-
induced DNA-damage and the amount of hypoxia within a tumour [9]. EGFR is 
involved in the regulation of intrinsic DNA-repair mechanisms and tumour cell 
proliferation via downstream pathway activation [10]. Tumour cell hypoxia induces 
radioresistance, directly as DNA-damage is maximized in the presence of oxygen and 
indirectly by promoting genetic instability [11,12]. An autocrine route has been 
described by which hypoxia induces expression of EGFR and its ligands [13,14] and in 
addition, EGFR can stabilize one of the key proteins in the hypoxia response namely 
hypoxia-inducible factor 1α (HIF-1α) [11]. Thus, EGFR is involved in all aspects of 
radioresistance. These resistance mechanisms play a role in HNSCC while EGFR is 
expressed at high levels in the majority of these tumours. This makes head and neck 
cancer the tumour archetype to further investigate these interactions.  
Various studies have shown that enhanced tumour cell proliferation can be 
counteracted by accelerated radiotherapy (AR) [15-17], while tumour hypoxia can be 
reduced using hypoxia-modifying treatment modalities [18]. A strategy that combines 
both AR and hypoxia modification is Accelerated Radiotherapy with CarbOgen (98% 
O2; 2% CO2) and Nicotinamide (ARCON) [19]. Results from clinical trials with ARCON 
show high locoregional control rates, in particular for oropharynx and larynx tumours 
[20,21].  
Both irradiation [22] and hypoxia [13] can enhance phosphorylation of EGFR thereby 
regulating intrinsic DNA-repair mechanisms [10] and cellular proliferation. We 
therefore hypothesized that EGFR could modulate the tumour response to accelerated 
radiotherapy with hypoxia modification. The purpose of our study is to investigate the 
predictive value of EGFR expression for ARCON in patients with advanced laryngeal 
carcinoma using material from a recently completed trial randomizing between AR 
and ARCON [21].  
 
42 
 
Materials and Methods 
Patients and treatment 
Three-hundred-and-forty-five patients with advanced laryngeal carcinoma were 
included in a randomized trial comparing AR and ARCON between April 2001 and 
February 2008 at seven centres for head and neck oncology (six from the Netherlands 
and one from the UK). The eligibility criteria were published previously [21]. Approval 
from the local Ethics Committee of the Radboud University Nijmegen Medical Centre 
was obtained and all patients gave written informed consent. Pre-treatment paraffin-
embedded biopsies were retrieved for immunohistochemical staining. 
 
Immunohistochemistry 
Sections from tumour biopsies were stained for EGFR expression as described 
previously with minor modifications [23]. Briefly, sections of 5µm were cut, 
deparaffinised and rehydrated through a graded ethanol series. Sections were 
incubated with proteinase-K (DAKO, Glostrup, Denmark) at 37°C. The primary 
antibody used was mouse anti-EGFR (DAKO M7239, Glostrup, Denmark) diluted 1:50 
in PAD. The secondary antibody was a biotinylated F(ab)’2-donkey anti-mouse IgG 
(Jackson Immunoresearch Laboratories Inc. West Grove, PA, USA), diluted 1:200 in 
PBS. Sections were counterstained with haematoxylin. 
 
Image acquisition and quantitative analysis 
All patient tissue sections were scanned with a Leica DM 6000 microscop 
(monochrome CCD camera (Retiga SRV) with an RGB filter (Slider module, QImaging, 
Burnaby, BC, Canada)) using IPlab imaging software (Scananalytics Inc., Fairfax, VA, 
USA). EGFR signal was scanned at 100X magnification. For every scanning session a 
background image was recorded. Extraction and separation of the individual colours 
from the DAB (brown) and haematoxylin (blue) signals was conducted using the RGB 
linear unmixing module in the TRI2-software (Randall Division and Gray Cancer 
Institute, London, UK). Based on a haematoxylin/eosin stained consecutive section, 
the tumour area of each section was delineated (necrotic areas and artefacts 
excluded). The EGFR fraction was defined as the tumour area positive for EGFR 
relative to the total tumour area. EGFR assays were performed blinded to the clinical 
endpoint.  
 
Statistical analysis 
Statistical analyses were performed on a Macintosh computer using Prism 4.0c 
(Hearne Scientific Software, Dublin, Ireland) software package. Comparison of 
baseline characteristics between patient groups was performed using the χ2-test for 
categorical variables, and using the independent Students t-test for continuous 
variables. Correlations between the EGFR fraction and ordinal tumour characteristics 
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(T-classification, N-classification, and histopathological grade) were assessed using 
the Spearman and the Kruskal-Wallis tests. To determine correlations between EGFR 
expression level and survival (locoregional control (LCR) and disease-specific survival 
(DSS)), Kaplan-Meier graphs with log-rank testing were used after dichotomizing the 
patients into two groups based on low and high EGFR fractions. p ≤ 0.05 was 
considered indicative of statistical significance. Multivariate analysis was performed 
using Cox proportional hazards analysis. Data are presented as hazard ratios (HR) 
with 95% confidence intervals (CI).  
 
Results 
Patients and treatment 
A total of 345 patients were randomized. From these, 73 patients were excluded from 
the current analysis, 39 because biopsy material could not be retrieved, 24 biopsies 
contained no or very little invasive carcinoma, and 10 because of poor quality due to 
mechanical damage during biopsy procedure or poor staining quality. Thus, 272 
histological confirmed squamous cell carcinomas of the larynx were available for 
analysis. The minimal duration of follow-up for all patients was two years with a 
median of 52 months for surviving patients. Patient and tumour characteristics were 
not significantly different between the AR and ARCON groups (Table 1). Treatment 
schedules and patient outcome have been published previously [21]. 
 
EGFR expression and correlation with tumour characteristics 
Most tumours showed membranous EGFR expression (median fraction 0.4), but there 
was a wide range (0.00-0.93) (Figures 1 and 2). Based on the bimodal distribution, 
patients were dichotomized at a fraction of 0.43, resulting in a low EGFR fraction 
group (n=144, 53%) and a high EGFR fraction group (n=128, 47%). There was no 
correlation between EGFR levels and clinical parameters except for a difference 
between EGFR high and low groups with regard to N-classification. Tumours with high 
EGFR expression were more frequently lymph node positive at time of presentation 
(Table 1). 
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Table 1. Patient and tumour characteristics of 272 laryngeal tumour patients 
 All (%) Treatment (%)  EGFR expression 
  ARCON 
(n=138) 
AR  
(n=134) 
p EGFR  
low 
EGFR 
high 
p 
Age 
Median (range) 
 
60.6 
(38 – 88) 
 
60.8 
(42 – 84) 
 
60.1 
(38– 88) 
 
0.65 
 
60.8 
(39-83) 
 
62.8 
(38-88) 
 
0.09 
Gender 
   male 
   female 
 
219    (81) 
53      (19) 
 
116   (84) 
22     (16) 
 
103   (77) 
31     (23) 
 
0.13 
 
112 (78) 
32  (22) 
 
 
107 (84) 
21 (16) 
 
0.23 
Primary site 
   glottic 
   supraglottic 
 
115    (42) 
157    (58) 
 
60    (43) 
78    (57) 
 
55     (41) 
79     (59) 
 
0.68 
 
58 (40) 
86 (60) 
 
 
57 (45) 
71 (55) 
 
   0.48 
T-classification 
   T2 
   T3 
   T4 
 
99      (36) 
133    (49) 
40      (15) 
 
46     (33) 
73     (53) 
19     (14) 
 
53     (39) 
60     (45) 
21     (16) 
 
 
0.40 
 
50  (35) 
76  (53) 
18  (12) 
 
49 (38) 
57 (45) 
22 (17) 
 
 
0.33 
N-classification 
   N0 
   N+ 
 
178    (65) 
94      (35) 
 
91     (66) 
47     (34) 
 
87     (65) 
47     (35) 
 
0.79 
 
104 (73) 
40    (27) 
 
74 (58) 
54 (42) 
 
0.01 
Histopathological  
differentiation grade 
  well 
  moderate 
  poor 
  n.k. 
 
 
17      (6) 
153    (56) 
47      (17) 
55      (20) 
 
 
9       (7) 
78     (56) 
29     (21) 
22     (16) 
 
 
8       (6) 
75     (56) 
18     (13) 
33     (24) 
 
 
 
 
0.18 
 
 
8  (5) 
79  (55) 
26  (18) 
31  (22) 
 
 
9  (7) 
74  (58) 
21  (16) 
24  (19) 
 
 
 
 
0.71 
n.k. not known 
 
Table 2. 5-years loco-regional control and disease-specific survival (%) and hazard ratio of 
patients treated with ARCON versus AR by EGFR expression fraction.  
Outcome end points AR ARCON p HR (95% CI) 
Disease-specific survival Low EGFR 82 91 0.08 0.38 
(0.12-1.12) 
High EGFR 77 78 0.54 1.23 
(0.58-2.86) 
Loco-regional control Low EGFR 69 88 0.009 0.34 
(0.14–0.79) 
High EGFR 75 71 0.85 1.07 
(0.53-2.15) 
HR, hazard ratio; CI, confidence interval  
 
 
 
 
 
EGFR expression, hypoxia and treatment response 
 
45 
 
 
Table 3. Multivariate analysis of clinical parameters and EGFR fraction 
 
Variables 
DSS AR 
p                HR 
              (95% CI) 
DSS ARCON 
p                HR 
                (95% CI) 
LRC AR 
p                  HR 
                (95% CI) 
LRC ARCON 
p                 HR 
                  (95% CI) 
T-classification  
(T2 vs T3 vs T4) 
0.156 1.54 
(0.85-2.79) 
0.726 1.14 
(0.55-2.39) 
0.349 0.79 
(0.49-1.29) 
0.261 1.39 
(0.78-2.51) 
N-classification  
(N0 vs N+) 
0.019 1.33 
(1.05-1.69) 
0.010 1.43 
(1.09-1.87) 
0.198 1.15 
(0.93-1.41) 
0.742 0.95 
(0.69-1.25) 
Histopathological 
grade  
(poor vs moderate vs well) 
0.571 0.96 
(0.81-1.12) 
0.367 0.88 
(0.66-1.17) 
0.321 0.94  
(0.84-1.06) 
0.283 1.08 
(0.34-1.25) 
EGFR fraction  
(low vs high) 
0.912 0.95 
(0.40-2.26) 
0.05 3.00 
(0.99-9.16) 
0.507 0.79 
(0.39-1.58) 
0.048 2.43 
(1.01-5.87) 
HR, hazard ratio; CI, confidence interval  
 
 
 
Figure 1. Range of the EGFR expression in laryngeal carcinoma (A) no expression; (B) 
intermediate expression and (C) high expression at 400x magnification. Scalebars represents 
100 µm.  
 
 
 
Figure 2. Distribution of EGFR expression based on EGFR fraction of whole tissue section in 272 
laryngeal tumours analysed in the ARCON trial. Line represents cut-off.  
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Associations between EGFR expression and treatment outcome 
No difference in 5-year disease specific survival (DSS) or locoregional control (LRC) 
was found between low and high EGFR expressing tumours in the AR arm (DSS 81% 
versus 78% and LRC 69% versus 75% respectively) (Figure 3a, c). In the ARCON arm, 
however, EGFR fraction was a significant prognostic factor for DSS and LRC. Patients 
with low EGFR levels had a better 5-year DSS (92% versus 77% p=0.01) and LRC 
(88% versus 72% p=0.02) compared to patients with high EGFR (Figure 3b, d).  
Table 2 shows the same data, now comparing AR against ARCON in the subgroups of 
patients with low and high EGFR fractions. ARCON improves 5-year LRC relative to AR 
in patients with low EGFR fraction (88% for ARCON versus 69% for AR p=0.009; 
Hazard Ratio (HR) 0.34) but there was no effect of ARCON in patients with high EGFR 
fraction. The same phenomenon was observed for DSS, albeit that the difference was 
borderline significant (p=0.08).  
The multivariate analysis (Table 3) confirmed EGFR fraction as an independent 
predictive factor for DSS and LRC in the patients treated with ARCON. After correction 
for T-, N-classification and histopathological grade, EGFR expression remained 
associated with LRC and DSS in the ARCON treatment arm (HR 2.43 CI 1.01-5.87 
p=0.048 and HR 3.00 CI 0.99-9.16 p=0.05 respectively). 
 
 
Figure 3. Kaplan-Meier estimates of (A) disease-specific survival in AR arm versus (B) in ARCON 
arm and (C) locoregional control in AR arm versus (D) in ARCON arm. Stratification is by the 
cut-off value of EGFR fraction. Comparison by log-rank test. 
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Discussion 
ARCON, a new treatment option for larynx carcinoma, combines AR with hypoxic 
modifiers to counteract enhanced tumour cell repopulation and reduce intratumoural 
hypoxia [19]. Selection of patients for new treatments is traditionally based on 
standard clinical and histopathological tumour characteristics. Predictive assays, 
based on molecular tumour markers and the oxygenation status of tumour cells, may 
provide better tools to select patients for new treatment approaches. EGFR is involved 
in all mechanisms of radioresistance and we therefore hypothesized that EGFR could 
be a powerful biomarker to predict tumour response to biology-based radiotherapy 
modifications. In the current study, we demonstrated that tumours with low EGFR 
expression respond better to ARCON compared to AR. EGFR expressing tumours were 
more likely to be node positive. However, as ARCON is most effective for regional 
control [21], this putative bias would indicate that the actual effect may be even more 
pronounced. In tumours with a high EGFR fraction, adding hypoxia modification to AR 
had no additive beneficial effect on outcome.  
Biopsies of patients with advanced laryngeal carcinoma were examined for EGFR 
expression. Similarly to other studies [4,24-26], we observed a wide variation in the 
EGFR expression levels. Most of the previous studies found a correlation between high 
(above median) EGFR expression and worse clinical outcome. One of the larger series 
including 155 head and neck cancer patients demonstrated that EGFR expression was 
a strong and independent prognostic indicator for LRC (HR 1.95 p=0.002) and overall 
survival (HR 1.75 p=0.006) [4]. In this study, all patients were treated with 
conventionally fractionated radiotherapy [4]. Two subsequent randomized trials 
consistently demonstrated that differences in outcome between high and low EGFR 
expressing tumours disappeared when accelerated radiotherapy was employed 
[26,27]. The latter improves tumour control only in tumours with high EGFR-
expression levels [26-28], most likely through suppression of EGFR-induced tumour 
cell proliferation.  
In the current study, both for the patient’s cohorts with high as well as low EGFR 
expressing tumours, 5-year LRC in the AR arm was around 70%, confirming the 
observations in the previously mentioned studies that acceleration radiation can 
counteract EGFR-associated radiation resistance [26-28]. Also in the tumours with 
high EGFR-expression treated with ARCON, a LRC rate of about 70% was obtained. 
However, the LRC for tumours with low EGFR levels treated with ARCON was 
significantly improved (88%, p=0.02). So, patients with low EGFR expressing tumours 
benefit from ARCON, whereas patients with high EGFR expressing tumours do not. 
Multivariate analysis indicated that EGFR expression is an independent predictor of 
LRC and DSS in patients treated with ARCON. 
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Table 4. Chi-square  
 EGFR low EGFR high 
Pimo low 21 28 
Pimo high 8 14 
p=0.402  
 
 
Figure 4. Fluorescence image from three xenografted larynx carcinomas showing (A, C & E) HIF-
1α (red) with vessels (blue) and (B, D & F) an adjacent section pimonidazole (green) in 
combination with EGFR (red) and vessels (blue). HIF-1α expression is present in pimonidazole 
positive (hypoxic) and negative (normoxic) areas. 100x magnification. Bar represents 100 µm.  
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From studies performed with EGFR inhibitors it is known that EGFR signalling is 
associated with the hypoxia response. Blocking EGFR can reduce intratumoural 
hypoxia possibly by normalization of the irregular dysfunctional tumour vasculature, 
thereby improving perfusion and oxygen delivery [29-31]. A major pathway in the 
hypoxia response is the HIF-pathway. HIF-1 is a heterodimer consisting of two 
subunits: HIF-1α and HIF-1β. Under normoxic conditions, HIF-1α is rapidly degraded, 
but under hypoxia it is stabilized [32]. Interestingly, EGFR itself can induce the HIF-1 
pathway in an oxygen-independent way by stabilizing HIF-1α, thereby activating the 
same target genes [33]. Tumour cells with high pre-treatment EGFR expression levels 
might be better able to rapidly activate downstream survival pathways, resulting in 
activation of the HIF-pathway, thereby thwarting the hypoxia modifying effect of 
ARCON. Low EGFR expressing tumours possibly lack this capacity and thus might be 
more likely to respond to ARCON. ARCON might reduce activation of the HIF-1 
pathway in hypoxic tumours but possibly cannot counteract the EGFR-induced HIF-
response in normoxic tumour cells. Therefore, in high EGFR expressing tumours, the 
defence mechanism through the HIF-1 pathway can still be active despite hypoxia 
modification. Figure 4 illustrates that in laryngeal tumours there is expression of HIF-
1α present in normoxic and EGFR-positive tumour areas, supporting this EGFR-
dependent HIF-response. Due to technical limitations HIF-1α could only be assessed 
qualitatively and not quantitatively. No correlation was found between overall 
fractions of EGFR and pimonidazole (Table 4). In the absence of hypoxia upregulation 
of HIF-1 may drive cells toward glycolysis, known as the Warburg effect, providing a 
growth advantage for tumour cells and resistance to ionizing radiation [11]. Hypoxia-
independent but EGFR-dependent upregulation of HIF-1α could account for the 
resistance of EGFR expressing tumours to hypoxia-modifying treatment. This 
hypothesis will be further explored in animal experiments. EGFR inhibitors also have 
an effect on the reoxygenation of tumour cells [34,35]. Possibly, in tumours with high 
EGFR expression signalling must be inhibited prior to ARCON treatment in order to 
benefit. 
 
Conclusion 
Current knowledge provides strong evidence that EGFR signalling plays an important 
role in the regulation of tumour cell survival during and after radiation treatment. 
EGFR evolved from a prognostic marker for patient outcome after conventional 
fractionated radiotherapy to a predictive biomarker for the effect of accelerated 
radiotherapy. In the current study we demonstrate that EGFR expression is also 
predictive for the response to hypoxic modification but with a reverse association. In 
patients with laryngeal carcinomas with low EGFR levels outcome can be further 
improved with ARCON, while there is no advantage of ARCON for patients with high 
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EGFR expressing tumours. In the latter, the effect of EGFR inhibition in combination 
with hypoxia modification needs to be explored.  
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Abstract 
Overexpression of EGFR correlates with decreased survival after radiotherapy in head 
and neck squamous cell carcinoma (HNSCC). However, the contribution of the 
activated form, pEGFR, and its downstream signalling (PI3-K/AKT) pathway is not 
clear yet.  
Fifty-eight patients with HNSCC were included in the study. pEGFR, pAKT, hypoxia, 
and vessels were visualized using immunohistochemistry. Fractions (defined as the 
tumour area positive for the respective markers relative to the total tumour area) 
were calculated by automated image analysis and related to clinical outcome. 
Both pEGFR (median 0.6%, range 0-34%) and pAKT (median 1.8%, range 0-16%) 
expression differed between tumours. Also, a large variation in hypoxia was found 
(median pimonidazole fraction 3.9%, range 0-20%). A significant correlation between 
pEGFR and pAKT (rs 0.44, p=0.004) was seen, however, analysis revealed that this was 
not always based on spatial coexpression. Low pAKT expression was associated with 
increased risk of regional recurrence (p<0.05, log-rank) and distant metastasis 
(p=0.04).  
The correlation between expression of pEGFR and pAKT is, indicative of activation of 
the PI3-K/AKT pathway through phosphorylation of EGFR. Since not all tumours show 
coexpression to the same extent, other factors must be involved in the activation of 
this pathway as well.  
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Introduction 
The Epidermal Growth Factor Receptor (EGFR) is a transmembrane tyrosine kinase 
that can be activated in response to binding of ligands or irradiation [1]. 
Phosphorylated EGFR (pEGFR) results in activation of various downstream pathways 
e.g. the phosphatidyl-inositol-3’ kinase (PI3-K)/Akt pathway [2]. After 
phosphorylation, AKT (pAKT) translocates to the cytoplasm and nucleus leading to 
transcription of genes responsible for cell cycle progression, cellular proliferation, 
DNA-damage repair, and apoptosis, processes contributing to tumour progression [3-
9]. Genes involved in the cellular response to hypoxia such as hypoxia-inducible 
factor-1α (HIF-1α) are also activated by pAKT [10].  
Several investigators have explored the role of EGFR or (p)AKT expression in patients 
with HNSCC. Mostly, they found a strong correlation between high EGFR expression 
and poor clinical outcome [11-15]. In addition, pAKT was found to be a significant 
predictor for local control [16,17]. There are indications that activation of the EGFR-
PI3-K/AKT pathway plays a role in radiation resistance with subsequently poor 
treatment outcome [18-21]. EGFR as well as pAKT are highly expressed in the 
majority of patients with head and neck squamous cell carcinoma (HNSCC) [6,15]. 
Overexpression of EGFR does not necessarily implicate phosphorylation of the 
receptor and activation of downstream pathways and there are, to our knowledge, no 
clinical studies relating pEGFR expression to clinical outcome. Besides activation 
through EGFR, the PI3-K/AKT pathway can be activated by several other mechanisms. 
These include activation through other receptor tyrosine kinases (RTKs), mutations in 
oncogenes upstream such as ras, loss of Phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN) [22], or amplifications or mutations of the gene PIK3CA, 
encoding the catalytic subunit of PI3K, or AKT itself [23,24].  
The purpose of this study was to examine the relative contribution of activated EGFR 
on the activation of the PI3-K/AKT pathway by investigating expression levels of 
pEGFR and pAKT, and spatial coexpression of these two markers. Hypoxic tumour 
cells with an activated EGFR-PI3-K/AKT pathway could have a survival advantage 
after treatment with radiotherapy. Therefore, the relationship between pEGFR, pAKT, 
and hypoxia was also investigated in these tumours.  
 
Patients and Methods 
Patients 
Between May 1998 and November 2001, 58 patients with HNSCC were included in our 
study at the Radboud University Nijmegen Medical Centre, Nijmegen. Patients with 
primary stage II to IV squamous cell carcinoma of the oral cavity, oropharynx, 
hypopharynx, or larynx were included. Patients were treated with radiotherapy alone 
or in combination with other treatment modalities such as chemotherapy or surgery. 
A written informed consent and approval from the local ethics committee was 
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obtained. Approximately 2 h before taking a biopsy, patients received a 20 min 
intravenous (i.v.) infusion of the hypoxia marker Hypoxyprobe-1 (500 mg/m2) 
(pimonidazole hydrochloride; NPI Inc., USA). A maximum dose of 1 g was given to 
patients >2m2. Biopsies were taken for routine diagnostic purposes before treatment 
and additional biopsies were taken for multiple marker analyses. The latter were 
immediately snap frozen in liquid nitrogen until immunohistochemical processing.  
 
Immunohistochemistry 
From the biopsy material, sections of 5 µm were cut, mounted on poly-l-lysine coated 
slides and stored at -80 °C. Prior to staining the sections were fixed in acetone of 4 °C 
for 10 min and rehydrated in phosphate buffered saline (PBS Klinipath, The 
Netherlands). Afterwards sections were incubated in primary antibody dilution (PAD, 
GeneTex Inc., USA) for 5 min at room temperature. Between all consecutive steps of 
the staining procedure, sections were rinsed in PBS three times for 5 min. The 
sections were incubated overnight at 4 °C with rabbit anti-pAKT antibody (Ser473) 
and goat anti-pEGFR antibody (Santa Cruz Biotechnology Inc., USA) diluted 1:50 and 
1:100 in PAD respectively. Adjacent sections were incubated overnight at 4 °C with 
rabbit anti-pimonidazole antibody (J.A. Raleigh, Department of Radiation Oncology 
and Toxicology, University of North Carolina, USA) and goat anti-pEGFR antibody 
1:1000 and 1:100 in PAD respectively. The second incubation was for 30 min at 37 °C 
with donkey anti-rabbit Alexa488 (Molecular Probes, The Netherlands) and donkey 
anti-goat Cy3 (Jackson Immunoresearch Laboratories Inc., USA) diluted 1:600 in PBS. 
The sections were stained for vessels by incubation with the mouse antibody PAL-E 
(Euro Diagnostica, The Netherlands) diluted 1:10 in PAD followed by incubation for 
30 min at 37 °C with chicken anti-mouse Alexa647 antibody (Molecular Probes) 
diluted 1:100 in PBS. The monoclonal antibody PAL-E is a marker for human 
endothelium, especially useful in frozen tissue sections. After the staining procedure, 
the sections were mounted in fluorostab (ProGen Biotechnik GmbH, Germany). 
 
Image acquisition 
The tissue sections were scanned with a digital image processing system consisting of 
a high-resolution 12-bit CCD camera (Micromax, Roper Scientific Inc., USA) on a 
fluorescence microscope (Axioskop, Zeiss, Germany) and a computer-controlled 
motorized stepping stage. Image processing was done using IPLab software 
(Scanalytics Inc., USA) on a Macintosh computer, as described earlier [25]. Each tissue 
section was sequentially scanned for the pimonidazole, pEGFR, pAKT and vessel 
signals at 200x magnification. The resulting composite gray value images were 
converted to binary images for further analysis. Thresholds for the fluorescence 
signals were interactively set at intensities where the steepest gradient occurred 
between background and foreground intensity levels. The corresponding composite 
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binary images were superimposed into one pseudocoloured image for visual 
evaluation.  
 
Analysis 
With H&E staining of a consecutive section, the tumour area of each section was 
delineated. This area was used as a mask in further analysis from which non-tumour 
tissue, necrotic areas, and artifacts were excluded. To calculate the amount of 
coexpression of pEGFR and pAKT, a binary closing operation on the pEGFR signal was 
done. The fractions of pEGFR (FpEGFR), pAKT (FpAKT) and hypoxia (HFpimo) were 
defined as the tumour area positive for the markers divided by the total tumour area. 
The vascular density (VD) was calculated as the number of vascular structures per 
square millimeter. The fraction of pAKT expressing cells positive for pEGFR was 
defined as the area that stained positive for both pEGFR and pAKT divided by the total 
pAKT-positive area (FpAKT[pEGFR]).  
To quantify the distribution of hypoxia, pEGFR, and pAKT in relation to the 
vasculature, zones were chosen at increasing distance from the surface of the nearest 
vessel (0-50 µm, 51-100 µm, 101-150 µm, 151-200 µm, and 201-250 µm). Hypoxic 
fraction, as well as fractions pEGFR and pAKT, and FpAKT[EGFR] were calculated within 
these vasculature zones.  
 
Statistics 
Statistical analyses were done on a Macintosh computer using Prism 4.0c (Hearne 
Scientific software, Ireland) software package. Data were log transformed passing 
normality testing. Correlations between parameters were assessed using the Pearson 
correlation test. To determine correlations between these parameters and categorical 
tumour characteristics (site, T-classification, N-classification, and histopathological 
grade) the Spearman correlation and the Kruskal-Wallis tests were used. To 
determine correlation between the parameters and risk (local and regional control, 
metastasis-formation) Kaplan-Meier graphs with log-rank testing was used. p≤0.05 
was considered indicative of statistical significance.  
 
Results 
Patients and treatment 
A total of 58 patients were included in this study. Pimonidazole was given to all 
patients before biopsy and none of them had adverse reactions. Table 1 shows the 
clinical characteristics of the patients. Seventeen biopsies were excluded from the 
analysis, six because they contained no or very little invasive carcinoma, eight because 
of poor quality due to mechanical damage during biopsy procedure or poor staining 
quality and three because the histological diagnosis was not squamous cell carcinoma. 
Thus, 41 histological confirmed squamous cell carcinomas were used for analysis. 
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There was no significant difference between the clinical parameters of the included 
and excluded patients. The median duration of follow-up for all patients was 25.7 
months and for surviving patients 86.6 months.  
 
Table 1. Patient and tumour characteristics of 41 HNSSC 
Age   
Mean (range) 
 
58 (36-85) 
 Number (%) 
Gender  
       Male  
       Female 
 
35 (85) 
6 (15) 
T-classification 
       T2 
       T3 
       T4 
 
14 (34) 
17 (41) 
10 (24) 
N-classification 
       N0 
       N+ 
 
11 (27) 
30 (73) 
Tumour site 
       Larynx 
       Hypopharynx 
       Oropharynx 
        Oral cavity 
 
20 (49) 
10 (24) 
9 (22) 
2 (5) 
Differentiation grade 
      Good 
       Moderate 
       Poor 
     
2 (5) 
21 (51) 
18 (44) 
 
 
Immunohistochemistry pEGFR, pAKT, pimonidazole and vessels 
Every biopsy was stained for pEGFR, pAKT or pimonidazole, and vessels. All markers 
gave bright fluorescent staining with little background except in areas of necrosis and 
stromal components of the tumour. Pimonidazole binding and pAKT expression was 
observed in the cytoplasm, while pEGFR staining was limited to the cell membrane 
(Figure 1). Coexpression of pEGFR and pAKT (FpAKT[pEGFR]) could identify tumour 
cells in which activated EGFR is linked to the activation of the PI3-K/AKT pathway. 
Figure 2 illustrates tumour cells in which pEGFR is coexpressed with pAKT, but also 
tumour cells with mismatch all within the same tumour section. The median values 
and range for all quantitatively measured parameters are summarized in table 2. A 
moderate but significant correlation between the overall expression of pEGFR and 
pAKT in the different tumours was found (rs=0.4 p=0.004) (Figure 3). There was no 
correlation between pimonidazole binding and expression of pEGFR or pAKT. As 
expected, pimonidazole binding increased with increasing distance from the blood 
vessels with highest fractions at >200 µm from the nearest vessel (Figure 3B). 
Expression of pEGFR and pAKT was found in normoxic as well as hypoxic tumour 
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cells. Most FpAKT[pEGFR] was observed at close distance to the vessels, mainly below 
100 µm, while less overlap was seen in the more hypoxic areas at greater distance 
(Figure 3B).  
 
 
 
Figure 1. Fluorescence image (grey values) at 400x magnification of (A) cytoplasmatic 
pimonidazole binding, and (B) pAKT expression, and (C) membranous pEGFR expression. Bar 
represents 50 µm.  
 
 
 
Figure 2. Fluorescence image showing membranous pEGFR and cytoplasmatic pAKT staining of 
a squamous cell carcinoma of the larynx. Grey scale image of (A) pEGFR, (B) pAKT, and (C) 
vessels (100x magnification). (D) Composite fluorescence image at 100x magnification and (E) 
detailed image at 400x magnification. Red: pEGFR, green: pAKT, blue: vessels. White arrow: 
coexpression, yellow arrow: cell with mismatch. Bar represents 100 µm (A-D) and 50 µm (E).  
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Figure 3. Fraction pEGFR versus pAKT in 41 head and neck squamous cell carcinomas (A) and 
distribution of HFpimo (black bars) and FpAKT[pEGFR] (grey bars) as a function of distance (µm) of 
nearest vessel (B). Plots show average values of 41 tumours (+/- SEM). *Significant difference 
compared to <50 µm. 
 
 
Table 2. Overall values for all parameters in 41 patients with HNSSC, measured with image 
analysis 
 HFpimo (%) FpEGFR 
(%) 
FpAKT (%) FpAKT[pEGFR] VD (N/mm2) 
Median 3.9 0.6 1.5 1.8 293 
Range 0-20 0-34 0-16 0-78 80-1440 
No. positive biopsies 31 (76%) 27 (66%) 30 (74%) - 41 (100%) 
 
 
Correlation between molecular markers and tumour characteristics  
A significant correlation was found between pAKT expression and N classification 
(p=0.001). Figure 4 shows that tumours with lymph node metastases had lower pAKT 
expression compared to lymph node negative tumours (median FpAKT 0.5% versus 
5.8%).  
Apart from a moderate, positive correlation of FpAKT[pEGFR] with T-classification (data 
not shown), no other correlations between the individual markers or coexpression of 
the markers and T- and N-classification, tumour site, or histological grade were found.  
 
Correlation between microenvironmental parameters and outcome 
Patients were dichotomized based on median expression values. A low pAKT 
expression was associated with a significantly shorter time to regional recurrence and 
on metastasis formation (log-rank p=0.04 resp. p<0.05) (Figure 5). The 5-year 
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regional recurrence and metastasis-risk was 40% and 64% for patients with low 
pAKT expression versus 6% and 36% for patients with high pAKT expression. There 
was no association between pEGFR expression and regional control or distant 
metastasis. Local control was not associated with pEGFR or pAKT expression.  
 
 
Figure 4. Expression of pAKT in node positive (N+) versus node negative (N0) tumours. Lines 
represent the median; p = 0.001. 
 
 
 
 
Figure 5. Kaplan-Meier estimates of regional recurrence (A) and metastasis-risk (B). 
Stratification by median pAKT value.  
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Discussion 
Overexpression of EGFR is commonly found in HNSCC [26]. Previous studies have 
revealed that higher expression of EGFR as well as pAKT is associated with a poor 
response to radiotherapy [13,16,17,20,21,27]. Activation of EGFR may result in 
activation of the PI3-K/AKT pathway. However, it is unknown to which extent this 
pathway is involved in radiation resistance in vivo. In our study, a heterogeneous 
group of head and neck cancer patients (with regard to site, classification, and 
treatment) was investigated for expression of pEGFR and pAKT, in relation to the 
microenvironment. In general, total EGFR is highly expressed (>90%) in HNSCC [11]. 
In our study the activated form, pEGFR, was observed in 66% of the tumours and 
expression of pAKT was found in 74% of the patients. The large variation in 
expression levels is in agreement with previous studies, which showed a high 
variation in expression of pEGFR [28-30] and pAKT [16,31,32] in other solid tumours 
as well. In addition, in the current study a positive relationship was found between 
pEGFR and pAKT, suggesting that EGFR signalling is one of the upstream regulators of 
the PI3-K/AKT pathway in HNSCC. A correlation between pEGFR and pAKT was found 
previously in patients with nasopharyngeal carcinoma [30]. Of note, in that study a 
clear distinction was made between the two known phosphorylation sites of AKT 
(Thr308 and Ser473), while in the present study one phosphorylation site of pAKT 
(Ser473) was investigated, in consensus with most other studies. The authors 
suggested that the increased activation of PI3-K/AKT signalling in nasopharyngeal 
cancer is most likely due to overexpression of pEGFR rather than mutations of the 
PIK3CA gene since they detected no mutations. 
Coexpression of pEGFR and pAKT might identify tumour cells in which EGFR is 
responsible for the activation of AKT and may therefore be a predictive factor for the 
response to EGFR-inhibitors, radiotherapy, or both. The PI3-K/AKT pathway triggers 
a cascade of responses, which are involved in all major radiation resistance 
mechanisms [18]. In the present study, a large variation was found in coexpression of 
pEGFR and pAKT, indicating that in head and neck cancer not all tumour cells that 
express pAKT are activated by EGFR and vice versa. Activation of AKT can occur by 
several mechanisms, independent of EGFR activation. These include amplifications or 
mutations of the gene PIK3CA [23,24], amplifications of AKT, activation by other RTKs 
or hetrodimerization of other ErbB family members [33], and decreased expression of 
PTEN [22]. PTEN, which acts a tumour suppressor, limits the activity of PI3K pathway 
and loss of PTEN results in unrestrained activation of AKT [5] and upregulation of the 
downstream proteins responsible for all major cancer growth mechanisms, thereby 
increasing radiation resistance. On the other hand, our results, i.e. pEGFR expression 
without pAKT expression, indicate that not in all cells activation of EGFR necessarily 
leads to activation of the downstream PI3-K/AKT pathway. Apart from of the PI3-
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K/AKT pathway, EGFR can activate other cell survival pathways including mTOR, 
RAS/MAPK, and the STAT/JAK pathway [34]. 
Coexpression, suggesting activation of AKT through pEGFR, is highest in parts of the 
tumour at a relatively short distance (below 100 µm) from the vessels. Figure 3B 
shows that in severely hypoxic tumour cells, pEGFR is of little influence on the 
activation of the PI3-K/AKT pathway. This suggests that activation of AKT in hypoxic 
cells is more commonly due to the other mechanisms previously mentioned. Also, 
activation of EGFR without pAKT expression was present, possibly leading to EGFR-
dependent activation of other pathways. It has been described earlier that hypoxia 
induces expression of EGFR, and in turn EGFR might enhance the cellular response to 
hypoxia and may therefore act as survival factor for hypoxic cells [35,36]. In response 
to hypoxia, cells have the ability to undergo adaptive changes [37], which can result in 
survival of the tumour cells and activation of the EGFR-PI3-K/AKT pathway under 
reoxygenated conditions. Even a small proportion of these reoxygenated cells may 
repopulate the tumour after treatment with radiotherapy. Recent studies show that 
inhibition of EGFR by the monoclonal antibody C225 leads to a decreased AKT 
phosphorylation, reduces tumour repopulation during radiotherapy and contributes 
to an improvement of tumour control [38,39].   
An inverse correlation between pAKT and N-classification was found. Patients with 
negative lymph nodes have a significantly higher expression of pAKT compared to 
patients with positive lymph nodes. This was previously also reported for patients 
with gastric carcinomas [40]. In addition to these findings, we found that low pAKT 
expression is associated with worse regional control, which, obviously, is directly 
linked to the higher incidence of lymph node metastases at presentation, and 
metastasis formation. These results are in contrast with several clinical studies were 
high pAKT expression is a prognostic factor for poor disease control [17,20,21]. 
However, recent studies demonstrated a role of pAKT in invasion and metastasis. One 
study showed that activation of AKT1 can suppress tumour invasion and lung 
metastasis formation in a mammary mice model [41]. Their hypothesis is that AKT1 
may hinder metastasis by preventing the degradation of the extracellular matrix and 
promoting differentiation of the mammary epithelium. In another study, with a breast 
epithelial cell line, downregulation of AKT1 enhanced EGF stimulated migration of 
cells [42]. The enhanced migration was accompanied by changes in protein expression 
that are consistent with epithelial-mesenchymal transition (EMT) characterized by 
loss of cell adhesion. Whether pAKT has the same role in HNSCC is under 
investigation.  
In conclusion, in a group of 41 head and neck carcinomas the presence of pEGFR, 
pAKT expression in relation to hypoxia and blood vessels was determined. Our data 
suggest that activation of the PI3-K/AKT pathway is only partly due to activation of 
EGFR in HNSCC. The high percentage of pEGFR and pAKT positive patients seen in this 
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study supports an important role for the EGFR-PI3-K/AKT pathway in the biology of 
head and neck cancer. Our data are consistent with a role for pAKT in cell migration 
and thwarting of metastasis. Currently, analysis of tumour material obtained from a 
randomized trial employing accelerated radiotherapy and oxygenation modification in 
patients with advanced laryngeal carcinoma (ARCON) [43] has started confirm these 
observations in a more homogenous group of patients. 
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Abstract 
E-cadherin is a transmembrane glycoprotein, involved in cell-cell adhesion and 
epithelial-mesenchymal transition (EMT). Vimentin is highly expressed in 
mesenchymal cells and is positively correlated with increased metastasis. Here we set 
out to determine the expression of E-cadherin and vimentin in head and neck 
squamous cell carcinomas (HNSCC). 
Twenty-six patients with primary stage II to IV HNSCC were included. E-cadherin and 
vimentin were visualized using immunohistochemistry, semi-automatically analyzed 
for expression patterns and correlated with the clinical behaviour of these tumours.  
A large variation in E-cadherin and vimentin expression was observed between 
tumours (median 17% range 0-51% respectively median 0% range 0-20%). Tumours 
with low E-cadherin expression showed a significantly higher incidence of metastasis 
formation compared to tumours with high expression (81% versus 19%, p=0.004). 
Enhanced expression of vimentin was associated with a trend towards a higher 
metastatic risk (33% versus 77%) compared to tumours without expression of 
vimentin. All patients with low E-cadherin and high vimentin expression (an EMT-
phenotype) developed distant metastases versus only 44% of the other patients 
(p=0.008).  
Loss of E-cadherin and gain of vimentin may be associated with enhanced migration of 
tumour cells, leading to higher metastatic risk of HNSCC patients.  
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Introduction 
Regional or distant metastasis formation is a major determinant in the prognosis of 
patients with head and neck squamous cell carcinoma (HNSCC). For these patients 
there is no curative treatment and they will die of their disease. Metastasis formation 
requires the spreading of cancer cells from their primary site to secondary locations in 
the body, the reattachment and growth at the new location. For tumour cells to 
migrate and form metastases, they must undergo changes in cell-cell adhesion, 
remodel cell-matrix adhesion sites and follow a chemoattractive path through the 
extracellular matrix; a phenomenon known as epithelial-mesenchymal transition 
(EMT) [1-3]. Loss of E-cadherin expression, leading to reduced cell-cell adhesion, as 
well as elevated levels of the mesenchymal marker vimentin, are distinctive events in 
EMT and common in metastatic carcinomas [1,2,4]. 
E-cadherin is a cell adhesion molecule present in the plasma membrane of most 
epithelial cells and has been implicated as a tumour suppressor in several types of 
human epithelial tumours, inhibiting migration and metastasis [3,5]. E-cadherin itself 
does not exhibit enzymatic activity. However, it has been shown that E-cadherin-
mediated-cell-cell adhesion can trigger a ligand-independent activation of the EGFR, 
regulating important cell signalling pathways such as PI3-K/AKT and Extracellular 
Signal-Regulated Kinase (ERK) [6-8]. On the other hand, E-cadherin inhibits ligand-
dependent activation of EGFR [9] (reviewed in Cavallaro 2011 [10]). Furthermore, 
increasing evidence indicates that the EGFR signalling pathways are able to regulate 
expression of the proteins involved in EMT [11,12].  Although some studies explored 
the expression of E-cadherin in HNSCC [13,14] and its relation with EGFR [15], it 
remains unclear whether there is a correlation between E-cadherin and the EGFR 
signalling pathways within tissue context.  
Vimentin is a intermediate-sized filament that is highly expressed in mesenchymal 
cells and is commonly used to identify cancer cells undergoing EMT based on a 
positive correlation of vimentin expression with increased invasiveness and 
metastasis [4].  
In HNSCC, radiotherapy is effective in early-stage tumours, but less effective for 
advanced tumours and only palliative in metastatic disease [16]. Loss of E-cadherin 
and gain of vimentin expression as well as activation of EGFR, are associated with 
tumour progression and EMT [4]. These considerations have led us to explore 
whether there is an association between E-cadherin and vimentin expression and the 
EGFR-PI3-K/AKT signalling pathway and/or metastasis formation in patients with 
head and neck cancer.   
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Patients and Methods 
Patients 
Twenty-eight patients with primary stage II to IV squamous cell carcinoma of the oral 
cavity, oropharynx, hypopharynx or larynx, treated at the Radboud University 
Nijmegen Medical Centre, Nijmegen, The Netherlands were included. Written 
informed consent was obtained from all patients after approval from the local ethics 
committee. Biopsies were taken for routine diagnostic purposes before treatment and 
during this procedure additional biopsies were taken from all patients for multiple 
marker analysis. The latter were immediately snap frozen in liquid nitrogen until 
immunohistochemical processing.  
 
Immunohistochemistry 
From the biopsy material, sections of 5 µm were cut, mounted on poly-l-lysine coated 
slides and stored at -80 °C. Prior to staining the sections were fixed in acetone of 4 °C 
for 10 min and rehydrated in phosphate buffered saline (PBS Klinipath, The 
Netherlands). Afterwards, sections were incubated in primary antibody diluent (PAD, 
GeneTex Inc., USA) for 5 min at room temperature. Between all consecutive steps of 
the staining procedure, sections were rinsed in PBS three times for 5 min. The 
sections were incubated overnight at 4 °C with goat anti-E-cadherin (Santa Cruz 
Biotechnology Inc., USA) 1:50 in PAD. The second incubation was for 30 min at 37 °C 
with donkey anti-goat Cy3 (Jackson Immunoresearch Laboratories Inc., USA) diluted 
1:600 in PAD. The sections were stained for vessels by incubation with the mouse 
antibody PAL-E (Euro Diagnostica, The Netherlands) diluted 1:10 in PAD. Next, 
sections were incubated for 30 min at room temperature with rabbit anti-vimentin 
(Santa Cruz Biotechnology Inc.) 1:200 in PAD followed by incubation for 45 min at 
37°C with donkey anti-rabbit Alexa488 (Molecular Probes, The Netherlands) and 
chicken anti-mouse Alexa647 antibody (Molecular Probes) diluted 1:100 in PAD. 
EGFR and pAKT (goat anti-EGFR and rabbit anti-pAKT 1:50, Santa Cruz Biotechnology 
Inc.) staining was combined with either E-cadherin or vimentin staining. After the 
staining procedure, the sections were mounted in fluorostab (Euro Diagnostica). 
 
Image acquisition and analysis 
The tissue sections were scanned with a digital image processing system consisting of 
a high-resolution 12-bit CCD camera (Micromax, Roper Scientific Inc., USA) on a 
fluorescence microscope (Axioskop, Zeiss, Germany) and a computer-controlled 
motorized stepping stage. Image processing was done using IPLab software 
(Scanalytics Inc., USA) on a Macintosh computer, as described earlier [17]. Each tissue 
section was sequentially scanned for all signals at 200x magnification. The resulting 
composite gray value images were converted to binary images for further analyses. 
Thresholds for the fluorescence signals were interactively set at intensities where the 
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steepest gradient occurred between signal to background intensity levels. The 
corresponding composite binary images were superimposed into one image for 
further image analysis. With help of an H&E staining of a consecutive section, the 
tumour area of each section was delineated. This area was used as a mask in further 
analysis from which non-tumour tissue; necrotic areas and artifacts were excluded. 
Vimentin expression in mesenchymal cells other than tumour cells (blood vessels, 
stromal components) was excluded from analysis. The fractions of expression of the 
markers were defined as the tumour area positive for the individual marker divided 
by the total tumour area.  
 
Statistics 
Statistical analyses were done on a Macintosh computer using Prism 4.0c (Hearne 
Scientific software, Ireland) software package. To determine correlations between 
parameters and categorical tumour characteristics (T-classification, N-classification, 
and differentiation-grade) χ2–test, Spearman correlation and Kruskal-Wallis tests 
were used. To determine associations with distant metastasis formation, Kaplan-
Meier graphs with log-rank testing were used. p≤0.05 was considered indicative of 
statistical significance.  
 
Results 
Patients and treatment 
Twenty-eight patients were included in this study. Two biopsies were excluded from 
the analysis because they contained very little invasive carcinoma. Thus, 26 
histologically confirmed HNSCC remained for analysis. Table 1 shows the clinical 
characteristics and treatment modalities of the patients. The median duration of 
follow-up was 25.9 months for all patients and 90.3 months for surviving patients. 
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Table 1. Patient and tumour characteristics of 26 HNSCC 
Age   
Mean (range) 
 
58 (36-80) 
 Number (%) 
Gender  
       Male  
       Female 
 
23 (88) 
3 (12) 
T-classification 
       T2 
       T3 
       T4 
 
7 (27) 
12 (46) 
7 (27) 
N-classification 
       N0 
       N+ 
 
7 (27) 
19 (73) 
Tumour site 
       Larynx 
       Hypopharynx 
       Oropharynx 
       Oral cavity 
 
12 (47) 
5 (20) 
6 (24) 
2 (9) 
Treatment 
       Radiotherapy alone 
       Chemoradiation 
       Radiation + surgery 
     
14 (54) 
5 (19) 
7 (27) 
 
E-cadherin and vimentin expression in head and neck cancer 
Staining of E-cadherin was limited to the cell membrane, while vimentin expression 
was observed in the cytoplasm. All markers gave bright fluorescent staining with little 
background except in areas of necrosis and stromal components of the tumour. E-
cadherin expression was present in 96% (25/26) of the biopsies and was found 
throughout the tumour tissue in all samples (Figure 1). Vimentin expression was 
present in 46% (12/26) of the biopsies and was observed in tumour cells surrounding 
blood vessels (Figure 1). Sporadically, in three biopsies, we found vimentin expression 
in solitary tumour cells further away from blood vessels. No correlation was observed 
between overall expression of E-cadherin and vimentin in the different biopsies. No 
associations were found between expression of these markers and T-stage, N-stage or 
differentiation grade. Tumours with low E-cadherin and high vimentin fractions could 
identify tumours in which EMT has occurred (Figure 2A). In addition, no associations 
were observed for patients with low E-cadherin and high vimentin and T- and N-stage 
or differentiation grade.  
 
Exploring the expression of E-cadherin and vimentin in relation to EGFR and pAkt 
might reveal associations between EMT and the EGFR-PI3-K/AKT pathway in patients 
with HNSCC. We observed tumour cells that show expression of E-cadherin, vimentin, 
EGFR and pAKT but also tumour cells without coexpression of more than one marker 
in the same tumour cell (Figure 1). We found a non-significant and weak association 
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between high E-cadherin fractions and high EGFR (rs 0.28 p=0.18) and pAKT 
expression (rs 0.27 p=0.19). Also, high vimentin expression was very weakly 
correlated with high EGFR (rs 0.14 p=0.48) and not with pAKT fractions (rs 0.02 
p=0.9). 
 
 
 
Figure 1. Fluorescence image at 200x magnification of (A) membranous E-cadherin (red), 
cytoplasmatic vimentin expression (green) and vessels (blue), (B) E-cadherin, pAKT (green) 
expression and vessels and (C) EGFR (red), vimentin expression and vessels.  Bar represents 50 
µm.  
 
 
EMT and distant metastasis formation 
Patients were dichotomized based on median expression values. A low expression of 
E-cadherin was significantly associated with a higher incidence of distant metastasis 
formation (p=0.004). The 5-year metastatic risk was 81% for patients with low E-
cadherin expression versus 19% for patients with high E-cadherin expression (Figure 
2B). Also, a high expression of vimentin showed a non-significant trend towards a 
higher metastatic risk (5-years risk 33% versus 77%, p=0.07) (Figure 2C). Figure 2D 
shows that patients with an EMT-phenotype (low E-cadherin and high vimentin 
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expression) have a significantly higher incidence of distant metastasis formation 
compared to the remaining patients (100% versus 44%, p=0.008). A further subgroup 
analysis is not realistic in view of the low total number of patients.  
 
 
Figure 2. Distribution and correlation of E-cadherin and vimentin expression based on whole 
tissue sections in 26 head and neck biopsies. Tumours with an EMT-phenotype are encircled 
(A) and Kaplan-Meier estimates of metastatic risk of (B) E-cadherin expression, (C) vimentin 
expression (stratification by the median value) and (D) EMT-phenotype. Comparison by log-
rank test. Numbers represent number of patients at risk.  
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Discussion 
Changes in cell adhesion molecules have an important role in increasing the motility 
of tumour cells and thereby enhancing migration and the formation of metastasis. 
During EMT, epithelial cells transform and attain mesenchymal-like properties, such 
as loss of E-cadherin and gain of vimentin expression. Here, we investigated a 
heterogeneous (with regard to site, classification and treatment) group of head and 
neck cancer patients for expression of E-cadherin and vimentin. We found that loss of 
E-cadherin significantly correlated with increased risk of distant metastasis formation 
while increased vimentin expression showed a trend towards a correlation with this 
endpoint. Of the 26 patients included in our study, 21 patients received only local 
treatment, while five patients received chemotherapy in addition to radiation. 
Chemotherapy reduces the risk of metastatic failure. Therefore, we repeated the 
analysis excluding those patients (data not shown). This, however, did not lead to 
relevant differences in results or conclusions.  
Previously, the expression of E-cadherin in primary carcinomas and nodal metastases 
of HNSCC and the relation to metastasis and patient survival has been explored 
[13,14]. The authors described more intense expression of E-cadherin in 
differentiated cells, but no correlation was found between reduced E-cadherin 
expression and survival (51 patients included in this study) [13]. This discrepancy in 
outcome might be explained by differences in staining techniques. Their group used 
the monoclonal antibody HECD-1, which detects the intracellular cytoplasmatic 
domain of the E-cadherin molecule, while a polyclonal antibody raised against the 
extracellular domain of E-cadherin was used in our study. A second study 
investigating E-cadherin expression and treatment outcome also showed no 
significant correlation with survival [14]. In contrast to our study, they dichotomized 
57 patients in negative and positive for E-cadherin and correlated this only to overall 
survival, while we divided patient based on median values and looked for the 
incidence of distant metastasis formation.   
Despite the fact that vimentin has been correlated with increased metastasis [4], it has 
not been extensively studied as prognostic marker in head and neck cancer treated 
with radiotherapy. Our results revealed that high vimentin expression shows a trend 
towards a higher incidence of metastasis formation. No correlation was observed 
between overall expression of E-cadherin and vimentin in the different biopsies, 
suggesting the presence of an intermediate phenotype with cells that passed only 
partly through the EMT. Although the numbers are small, we were able to identify a 
subset of tumours with low E-cadherin together with high vimentin fractions. These 
patients showed a significantly higher risk of metastasis formation compared to the 
tumours without this EMT-phenotype. A confirmatory study is currently being 
performed in a larger and more homogeneous cohort of patients with laryngeal 
carcinoma.  
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Overactivation of EGFR signalling pathways is related to more aggressive tumour 
behaviour and correlates with poor prognosis in patients with HNSCC [18-20]. 
Activation of the EGFR signalling cascades in turn can lead to transcription of genes 
responsible for cell cycle progression, cellular proliferation, DNA repair and 
metastasis [21,22]. EGFR signalling pathways are highly expressed in many human 
cancers, including carcinoma of the head and neck [23,24], leading to radioresistance 
and tumour progression [18,19,25]. Increasing evidence indicates that the EGFR 
signalling pathways can regulate expression of proteins involved in EMT in several 
tumour types [11,12]. This is supported by a study using a head and neck tumour 
model that highly expressed E-cadherin and that was very sensitive to the anti-EGFR 
antibody Cetuximab, whereas a tumour line that expressed vimentin revealed low 
sensitivity [26]. We observed that not all tumour cells that express E-cadherin also 
express EGFR although we found a weak association between high E-cadherin and 
high EGFR fractions. The relevance of this correlation for the prognosis of patients 
with head and neck cancer is not clear and could be due to the small number of 
patients. 
The role of the EGFR down-stream target AKT in cell migration and metastasis is less 
clear. One study [27] showed that expression of AKT can induce EMT and promote 
enhanced motility and invasiveness in squamous cell carcinoma lines, while another 
study demonstrated that activation of AKT1 might suppress tumour invasion [28]. Irie 
et al described isoform-specific functions of AKT in the regulation of cell migration 
and invasion [29]. AKT1 down-regulation enhanced migration in response to EGF 
stimulation and induced an EMT phenotype: repressed E-cadherin expression and a 
small increase in vimentin expression. In contrast, AKT2 down-regulation does not 
enhance migration or alter expression of E-cadherin, but it does reduce vimentin 
expression. 
In conclusion, our results show that a phenotype resembling EMT in patients with 
HNSCC, with loss of E-cadherin and gain of vimentin, is associated with a significantly 
higher risk of distant metastasis formation. If confirmed, this observation may have 
important implications for treatment decisions (e.g. (neo)adjuvant chemotherapy).     
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Abstract  
The PI3-K/AKT pathway plays an important role in tumour cell survival and 
radioresistance. Targeting AKT is considered as a treatment option in several solid 
tumour types. Recently; however, we found in head and neck cancer patients that low 
phosphorylated (p)AKT expression in the primary tumour was associated with lymph 
node metastasis. Here, we set out to validate this finding in an independent cohort of 
laryngeal cancer patients and to examine the effect of pAKT inhibition on epithelial-
mesenchymal transition (EMT) of laryngeal cancer cells. 
Seventy-eight patients with laryngeal cancer were included. EGFR, pAKT, vimentin, E-
cadherin, hypoxia and blood vessels were visualized in biopsy material using 
immunohistochemistry. Positive tumour areas and spatial relationships between 
markers were assessed by automated image analysis. In six laryngeal cancer cell lines 
E-cadherin and vimentin mRNA was quantified by real-time polymerase chain 
reaction and by immunohistochemistry before and after treatment with the pAKT 
inhibitor MK-2206.  
A significant correlation was found between low pAKT in the primary tumour and 
positive lymph node status (p=0.0005). Tumours with lymph node metastases had 
approximately 10-fold lower median pAKT-value compared to tumours without 
lymph node metastases, albeit with large inter-tumour variations, validating our 
previous results. After inhibition of pAKT in laryngeal cancer cells with MK-2206 
upregulation of vimentin and a downregulation of E-cadherin occurred, consistent 
with EMT. 
Low pAKT expression in larynx tumours is associated with lymph node metastases. 
Further, inhibition of pAKT in laryngeal cancer induces EMT predisposing for an 
increased metastatic risk.  
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Introduction 
Radiotherapy is an effective treatment modality for head and neck cancer, in 
particular for early-stage tumours. In advanced stages the effectiveness of 
radiotherapy has been improved by the addition of chemotherapy or the Epidermal 
Growth Factor Receptor (EGFR) inhibition by cetuximab [1,2]. Currently, the 
combination of radiotherapy with inhibitors of pAKT, a signaling molecule 
downstream of EGFR, is under clinical investigation. However, recent findings showed 
an association of low pAKT with increased metastases formation in patients with head 
and neck cancer treated with radiotherapy [3]. This raises the question if pAKT 
inhibition in head and neck cancer may actually promote a more metastatic phenotype 
leading to a worse clinical outcome.  
AKT, a serine/threonine protein kinase, is one of the most frequently hyperactivated 
signaling pathways in human cancers. It is phosphorylated by phosphatidylinositide-
3-kinase (PI3-K) after activation through receptor tyrosine kinases (RTK) like EGFR. 
After phosphorylation at the plasma membrane AKT translocates to the cytosol and 
nucleus to activate its substrates [4]. Although the main known biological 
consequences of AKT activation are proliferation, growth and tumour-induced 
angiogenesis, the prognostic significance of AKT activation in cancer is inconclusive. 
High pAKT expression has been associated with poor [5] and favorable prognosis [6] 
in different types of tumours.  
Three isoforms of AKT exist, of which AKT1 and AKT2 are ubiquitously expressed. All 
are activated by similar mechanisms in PI3-K signaling [7]. The different isoforms of 
AKT all have cancer-type specific roles in cell migration and metastasis formation. In 
prostate cancer cells, both AKT1 and AKT2 function as negative regulators of cell 
migration and invasion. Downregulation of AKT1 but not AKT2 in breast cancer cells 
caused an enhancement of cell migration [8]. This enhanced migration was 
accompanied by phenotypical changes that are consistent with the phenotypical 
change of epithelial-mesenchymal transition (EMT). In EMT, the expression of 
epithelial markers (E-cadherin) is suppressed and the expression of mesenchymal 
markers (vimentin) is enhanced, leading to reduced cell-cell adhesion and possibly 
increased cell migration. Earlier investigations show more metastases and a reduced 
patient survival when tumour cells exhibit a more mesenchymal phenotype [9,10].  
MK-2206, currently used in clinical trials, is an allosteric inhibitor of AKT 
phosphorylation [11].   
The purpose of this study was to validate the association of pAKT with lymph node 
metastasis in an independent, homogeneous cohort of patients with larynx cancer. 
Furthermore, we studied the effect of MK-2206-induced pAKT inhibition on the 
expression of two major proteins involved in EMT, E-cadherin and vimentin, in 
laryngeal cancer cell lines.  
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Patients and methods 
Patients 
Between April 2001 and January 2008, 78 patients with squamous cell carcinoma of 
the larynx were included. All patients were treated in the Radboud University 
Nijmegen Medical Centre Nijmegen, The Netherlands. The study was approved by 
from the local ethics committee and all patients provided written informed consent. 
Patients were treated with (accelerated) radiotherapy alone or surgery with post-
operative radiotherapy. Approximately 2 h before taking a biopsy, patients received a 
20 min intravenous (i.v.) infusion of the hypoxia marker Hypoxyprobe-1 (500 mg/m2) 
(pimonidazole-hydrochloride; NPI Inc.). Biopsies were taken for routine diagnostic 
purposes and additional biopsies were taken for multiple marker analyses. The latter 
were snap frozen in liquid nitrogen.  
 
Immunohistochemistry  
Frozen tumour sections (5 µm) were mounted on poly-L-lysine coated slides and 
stored at -80°C. Next sections were fixed in cold acetone (4°C, 10 min) and rehydrated 
in phosphate buffered saline (PBS Klinipath, The Netherlands). Between all steps of 
the staining procedure, sections were rinsed in PBS three times. Sections were 
incubated overnight at 4°C with rabbit anti-pAKT antibody (Ser473) and goat anti-
EGFR antibody diluted 1:50 in primary antibody dilution (PAD, GeneTex Inc.). 
Adjacent sections were incubated overnight with rabbit anti-pimonidazole antibody 
(J.A. Raleigh, University of North Carolina, USA) and goat anti-EGFR antibody (1:1000 
and 1:50 in PAD respectively). A third adjacent tumour section was incubated with 
goat anti-E-cadherin 1:50 in PAD. For all sections, the second incubation was with 
donkey anti-rabbit Alexa488 (Molecular Probes, The Netherlands) or donkey anti-goat 
Cy3 (Jackson Immunoresearch Laboratories Inc.) diluted 1:600 in PBS for 30 min at 
37°C. The sections were stained for vessels by incubation with the mouse anti-human 
endothelium antibody PAL-E (Euro Diagnostica, The Netherlands) (1:10 in PAD) 
followed by incubation for 30 min at 37°C with chicken anti-mouse Alexa647 antibody 
(Molecular Probes) (1:100 in PBS). Next, sections stained for E-cadherin were 
incubated with rabbit anti-vimentin 30 min (room temperature, 1:200 in PAD) 
followed by incubation for 45 min with donkey anti-rabbit Alexa488 1:100 in PAD. 
Antibodies were purchased from Santa Cruz Biotechnology Inc., CA. After the staining 
procedure, the sections were mounted in fluorostab (ProGen Biotechnik GmBH, 
Germany). UT-SCC cells cultured on chamberslides were stained similarly.     
 
Image acquisition 
The tumour sections were scanned with a digital image processing system on a 
fluorescence microscope (Axioskop, Zeiss, Germany) and a computer-controlled 
motorised stepping stage. Image processing was done using IPLab (Scanalytisc Inc.) 
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and ImageJ software (National Institute of Health, USA) on a Macintosh computer, as 
described earlier [12,13]. Each section was sequentially scanned for all signals at 200X 
magnification. The resulting composite grey value images were converted to binary 
images for analyses. Thresholds for the fluorescence signals were interactively set at 
intensities where the steepest gradient clearly distinguishing between signal and 
background. The corresponding composite binary images were superimposed into 
one pseudo-coloured image for visual evaluation.  
 
Analysis 
With H&E staining of a consecutive section, the tumour area of each section was 
delineated. This area was used as a mask in further analysis from which non-tumour 
tissue; necrotic areas and artefacts were excluded. Vimentin expression in 
mesenchymal cells other than tumour cells (blood vessels, stromal components) was 
excluded from analysis. The fractions of marker expression were defined as the 
tumour area positive for the individual marker divided by the total tumour area.  
To quantify the distribution of hypoxia, EGFR and pAKT in relation to the vasculature, 
zones were chosen at increasing distances from the nearest vessel (0-50, 51-100, 101-
150, 151-200, and >201 µm). Hypoxic fractions, as well as fractions EGFR and pAKT 
were calculated within these vascular zones.  
 
Cell culture 
Six human laryngeal cancer cell lines (UT-SCC lines, University of Turku, Finland) 
were cultured in vitro. All patients from whom the cell lines were derived were N0 
except UT-SCC9, which was N1. Cells were cultured under humidified conditions 
(37°C, 5% CO2), and passaged twice weekly in DMEM containing 2mM L-glutamine, 
1% nonessential amino acids, 20 mM Hepes, 10 units/ml penicillin, 10 units/ml 
streptomycin and 10% foetal bovine serum. To determine the effect of low pAKT 
levels in tumours, cell lines were treated overnight with 1 µM of the pAKT inhibitor 
MK-2206 (Selleckchem, Houston, USA) under standard normoxic conditions. 
 
qPCR  
To determine the effect of pAKT inhibition on EMT, cells were lysed, RNA isolated, and 
E-cadherin and vimentin mRNA quantified using qPCR. Total RNA was isolated with 
total RNA purification kit (Norgen Biotek Corp., Canada) with on-column DNAse 
treatment. RNA was reversed-transcribed using I-script (Bio-Rad) and cDNAs were 
amplified with specific primers (E-cadherin forward: AGGCCAAGCAGCAGTACATT,  
reverse: ATTCACATCCAGCACATCCA; Vimentin forward: 
ACACCCTGCAATCTTTCAGACA, reverse: GATTCCACTTTGCGTTCAAGGT) using Sybr 
Green Master Mix (Applied Biosystems, Nieuwerkerk a/d IJssel, the Netherlands) on a 
CFX96 realtime-PCR detection system (Bio-Rad Laboratories Inc. Richmond, CA). All 
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samples were normalized for levels of hypoxanthine-guanine phosphoribosyl-
transferase (HPRT) expression.  
 
Western blot 
To verify if pAKT expression was inhibited by MK-2206 cells were lysed, debris was 
removed and protein was quantified using a standard Bradford absorbance assay. 
Proteins were separated by SDS-PAGE and blotted onto PVDF membrane. Membrane 
was incubated with a pAKT (Ser473) antibody (Cell Signaling Technology, Danvers, 
MA) followed by incubation with HRP-conjugated antibody goat anti-rabbit IgG (Santa 
Cruz Biotechnology, Santa Cruz, USA) and detected with an ECL chemiluminescence 
system. Protein quality and loading check was performed with α-tubulin (Calbiochem 
San Diego, CA)  
 
Statistics  
Statistical analyses were done on a Macintosh computer using Prism 4.0c (Hearne 
Scientific software, Ireland) software package. To determine correlations between 
parameters and categorical tumour characteristics (T-classification, N-classification 
and differentiation grade) Spearman correlation and Kruskal-Wallis tests were used.  
p ≤ 0.05 was considered statistical significant.  
 
Results  
Patients  
A total of 78 patients were included in this study. Pimonidazole was given to all 
patients before biopsy taking and none of them had adverse reactions. Nine biopsies 
were excluded from analysis, three because they contained no or little invasive 
carcinoma, four because of poor staining quality and two because histological 
diagnosis was not laryngeal carcinoma. Thus, 69 histological confirmed laryngeal 
carcinomas were used for analysis (Table 1).  
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Table 1. Patient and tumour characteristics  (N=69) 
Age   
Mean (range) 
 
61 (38-83) 
 Number (%) 
Gender  
       Male  
       Female 
 
50 (72) 
19 (28) 
T-classification 
       T2 
       T3 
       T4 
 
29 (42) 
27 (39) 
13 (19) 
N-classification 
       N0 
       N+ 
 
42 (61) 
27 (39) 
Tumour site 
       Glottic 
       Supraglottic 
       Subglottic 
       Transglottic 
 
20 (29) 
43 (62) 
2     (3) 
4     (6) 
Diff. grade 
       Good 
       Moderate 
       Poor 
       Not classified 
     
5     (7) 
41 (60) 
18 (26) 
5     (7) 
 
 
EGFR, pAKT, E-cadherin & vimentin expression in larynx carcinoma 
Staining of EGFR and E-cadherin was limited to the cell membrane, while pAKT and 
vimentin expression was observed in the cytoplasm (Figure 1). As expected, 
pimonidazole binding increased at increasing distances from the blood vessels with 
highest fractions at >150 µm from the nearest vessel. Expression of EGFR was 
predominantly found in better-oxygenated areas close to blood vessels, while pAKT 
expression was higher in pimonidazole positive, hypoxic areas (Figure 2).  
There was a strong significant negative correlation between pAKT expression and N-
stage (p=0.0005). Laryngeal carcinomas with lymph node metastases had much lower 
pAKT expression compared to tumours with negative lymph node (median fraction 
0.08 versus 0.009, Figure 3). No further associations were found between expression 
of EGFR or pAKT and other clinical parameters.  
Previously, we hypothesized that pAKT attenuates the transition of epithelial cells to a 
more mesenchymal phenotype, thereby explaining lymphatic invasion specifically in 
pAKT negative tumours. We therefore explored E-cadherin and vimentin expression 
in relation to pAKT. Some pAKT positive cells were also positive for E-cadherin, while 
others coexpressed pAKT and vimentin.   
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Figure 1. Immumofluorescene image of a biopsy of a laryngeal carcinoma showing (A) 
membranous EGFR staining (red) and cytoplasmatic pAKT staining (green) (100X 
magnification) and (B) membranous E-cadherin staining (red) and cytoplasmatic vimentin 
(green) (200X magnification). Scalebars represent 100 µm.   
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Figure 2. Distribution of pimonidazole (black), fraction EGFR (light gray) and pAKT (dark gray) 
as a function of distance (µm) from nearest vessel. Average values of 69 tumours (± SEM). ** 
p<0.01 *** p< 0.0001 significant difference compared to <50µm zone. 
 
 
 
 
 
Figure 3. Expression of pAKT in node positive (N+) versus node negative (N0) tumours. Lines 
represent median values. p=0.0005  
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pAKT inhibition leads to reduced E-cadherin and upregulation of vimentin in larynx 
tumour cells   
To place the results from the patient data in context, we examined if inhibition of 
pAKT with MK-2206, a novel allosteric pAKT inhibitor, would induce EMT in laryngeal 
carcinoma cells. We found that pAKT inhibition after 24 or 48 hr incubation 
upregulated vimentin mRNA in all six cell lines, although not all differences were 
statistically significant. In four cell lines mRNA of E-cadherin was reduced (Figure 
4A.). Two cell lines, UT-SCC 9 and UT-SCC 29, downregulated E-cadherin and 
upregulated vimentin mRNA within 24 hr of pAKT inhibition, which is a classical 
indication of EMT. All other cells lines showed a non-significant trend towards EMT. 
Figure 4B shows that treatment with 1 µM MK-2206 inhibited expression of pAKT 
assessed by the means of western blotting.   
To investigate the effect of pAKT inhibition on protein expression of EGFR, E-cadherin 
and vimentin we immunohistochemically stained these markers in UT-SCC 9 cells. 
This tumour cell line, showing an EMT-like transition with qPCR (Figure 4A), was 
cultured on chamberslides. Figure 4C&D clearly shows that after pAKT inhibition a 
downregulation of E-cadherin expression and an upregulation of vimentin expression 
occur. Unexpectedly, we found expression of nuclear EGFR after treatment with MK-
2206 (Figure 5).  
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Figure 4. mRNA levels of Ecadherin and vimentin relative to HPRT after 24, 48 or 72 hr pAKT 
inhibition (A). *Represent significant difference compared to control cells. Downregulation of 
pAKT was shown by Western Blot analysis; numbers below the bands are densitometry values 
of pAKT normalized against AKT values  (B). Fluorescence images (200X magnification) of E-
cadherin (red) and vimentin (green) before (C) and after (D) pAKT inhibition. Scalebars 
represent 100 µm 
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Figure 5. UT-SCC cells after treatment (B) with MK-2206 for 24 hr an upregulation of nuclear 
EGFR was present, control cells showing membranous EGFR (A). Magnification 200X, scalebars 
represent 100 µm. 
 
 
Discussion 
Anti-EGFR targeted therapy in combination with radiotherapy has been shown to 
improve survival but only in a small percentage of patients with head and neck cancer 
[2]. Therefore, new targets are tested for their usefulness as treatment options. The 
PI3-K/AKT pathway is a downstream effector of EGFR, and AKT is an interesting 
candidate for therapeutic purposes because, like EGFR, it is often overexpressed in 
HNSCC [14]. However, we predominantly found EGFR expression in better-
oxygenated areas of the tumour, while pAKT levels were higher in hypoxic areas. This 
finding supports the evidence that not only EGFR, but multiple receptors can activate 
AKT. It also points out the need for improved targeted therapies, as EGFR inhibition 
does not automatically lead to inhibition of AKT-dependent survival mechanisms.  
Although it is generally accepted that activation of AKT leads to enhanced tumour 
growth and poor outcome, preclinical studies indicate that low AKT1 expression can 
lead to more metastases [8]. Recently, we found an association between low pAKT 
expression and positive nodal status of HNSCC patients prior to treatment [3]. We 
speculated that pAKT inhibition could stimulate metastasis formation in these 
tumours. Here, we have validated this observation in an independent cohort of 
laryngeal cancer patients. Patients presenting with lymph node metastases appear to 
have 10-times lower median pAKT expression levels in their primary tumour 
compared to patients without nodal metastases, although there are large variations 
between tumours and an overlap between both groups exists. This further supports 
the evidence that AKT is associated with metastatic prevalence of HNSCC.  
Different AKT isoforms are found to have distinct functions in tumour progression 
depending on tumour type. Enhanced AKT1 signaling promotes tumour progression 
through increased cellular survival mechanisms, whereas AKT2 reportedly inhibits 
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cancer growth [15]. AKT1 reduces while AKT2 enhances cell invasion and migration 
in breast and ovarian cancer but, on the other hand, no different isoform specific 
functions were found in prostate cancer [8,15,16] This indicates that treatment with 
pAKT inhibitors, aimed at both isoforms together, might inhibit growth of some 
tumours, but could also induce more pronounced metastatic behavior in others. These 
findings highlight the necessity for isoform-specific inhibitors. For example, AKT1 
inhibition may not be recommended in breast and, maybe, in head and neck cancer 
patients, as it may promote cell migration, whereas in other cancer types, such as 
prostate cancer, all AKT inhibition may be beneficial to inhibit tumour progression.  
Also, in vivo, there are contradicting results on the role of AKT in metastasis 
formation. In mice with mammary tumours overexpressing ErbB2 AKT1 coexpression 
impaired metastases while AKT2 coexpression increased the proportion of mice with 
metastasis [8,17]. Inhibition of pAKT with MK-2206 in an orthotopic model of a 
tongue tumour led to reduced primary tumour size and less cervical metastases [11]. 
When testing different clonal mammary tumour cell lines Dillon et al. found that 
highly metastatic clones displayed upregulated AKT2 expression compared to less 
metastatic clones. Interestingly, the highest pAKT levels, all due to elevated AKT1 
phosphorylation, were found in the low metastatic clones [17]. The data presented in 
the current study also showed a higher pAKT level in tumours without lymph node 
metastasis.  
Although downstream effectors of AKT isoforms remain to be identified, candidate 
pathways have been suggested. One study found that AKT1 could inhibit breast cancer 
cell invasion through nuclear factor of activated T-cell (NFAT) downregulation. 
Another study showed that the enhanced migration observed with AKT1 
downregulation was accompanied by changes in protein expression that are 
consistent with EMT [8]. Metastasis formation not only involves EMT, but also 
detachment from the primary tumour site and escape of single cells into the blood or 
lymph vessels followed by reattachment, transition back to epithelial state and 
angiogenesis to form a secondary tumour [9]. We hypothesized that pAKT can protect 
cells from EMT. Therefore, reducing pAKT in tumour cells should lead to specific up or 
down regulation of proteins involved in EMT. In six laryngeal carcinoma cell lines we 
tested whether reducing pAKT with MK-2206, a pAKT inhibitor, leads to 
downregulation of E-cadherin and upregulation of vimentin. In all cell lines EMT was 
induced to some degree, indicating that inhibition of pAKT in laryngeal tumour cells 
possibly leads to a higher metastatic risk.  
Another explanation why low pAKT can lead to more metastases could be the 
existence of a negative feedback loop. Recently was found that inhibition of mTOR by 
rapamycin relieves a feedback loop, activating IGF signaling leading to activation of 
PI3K and ERK signaling. This was found also in patients thereby decreasing the 
therapeutic efficacy of the drug [18]. Others provided evidence that inhibition of AKT 
induces HER3 expression and other RTKs by a similar feedback loop. By inhibition of 
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AKT the downstream effects will be suppressed but other RTKs-driven signaling 
pathways, like mTOR and MDM2, will be activated, leading to activation of proteins 
and genes involved in migration of tumour cells, explaining the effect of low pAKT 
expression on metastatic potential [19].  
An unexpected finding after pAKT inhibition was the induction of nuclear EGFR. EGFR 
is predominantly present on the cell membrane, however recently nuclear localisation 
of EGFR has been identified.  Nuclear EGFR was found to act as transcriptional 
activator of various oncogenic genes; it is associated with increased G1/S phase 
progression and proliferation of tumour cells. Nuclear EGFR correlates with poor 
outcome in patients with breast, oropharyngeal and ovarian cancer [20]. Also, 
downregulation of pAKT induces RTK activity including EGFR and HER3 in breast 
cancer cells but no distinction was made between nuclear and membranous EGFR 
[19]. In the present study we could clearly see in which subcellular compartment 
EGFR is upregulated. Whether this MK-2206-induced nuclear EGFR is a tumour-
specific effect of laryngeal cancer and how this affects radioresistance requires further 
investigation.  
 
Conclusion 
Several ongoing clinical trials use pAKT inhibitors to modulate treatment response. 
Inhibition of pAKT is expected to lead to a better patient outcome by reducing 
downstream signaling of tumour survival mechanisms. The results from our work and 
studies by others describe a complex picture in which pAKT inhibition should be 
considered in a cancer-type specific manner. We recommend that new pAKT 
inhibitors should be tested for potential stimulation of EMT and be introduced in the 
clinic prudently.  
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Discussion  
Due to a preference for organ preservation, the first choice of treatment of early-stage 
tumours is often radiotherapy. Tumour cell response to radiation depends on 
activation of different receptor proteins and signalling pathways; on differences in 
intrinsic radioresistance, tumour cell proliferation and the amount of hypoxic regions 
within a tumour [1]. All these aspects are, to some extent, under the control of the 
EGFR-PI3-K/AKT signalling pathway. The aim of this thesis was to investigate the 
activation of this pathway, which is often overexpressed in solid tumours including 
head and neck squamous cell carcinomas (HNSCC), the tumour model that was used in 
this thesis. In order to understand the involvement of this pathway in radiation 
responsiveness and in an attempt to disentangle the interactions with the tumour 
microenvironment, we evaluated expression levels of key molecules in relation to 
each other and to microenvironmental factors, like the presence of hypoxia and 
vasculature. In this chapter, the relevance of the EGFR-PI3/K-AKT pathway for 
radiation responsiveness is discussed and future considerations are highlighted. 
 
EGFR and downstream signalling pathways 
EGFR and its downstream signalling pathways have been frequently investigated with 
regard to patient outcome [2-4]. The current knowledge on EGFR-regulated signalling 
pathways provides strong evidence that EGFR activation plays an important role in 
the regulation of tumour cell survival and treatment resistance. EGFR is a 
transmembrane protein with intrinsic tyrosine kinase activity [4] and activation of 
EGFR causes autophosphorylation (pEGFR), subsequent receptor internalisation and 
stimulation of many signalling pathways including the phosphatidylinositol-3-kinase-
AKT (PI3-K/AKT) pathway [1,5,6]. Once activated, these pathways are responsible for 
tumour cell proliferation, DNA-damage repair, migration, angiogenesis, and 
consequently resistance to treatment. Radiotherapy combined with blockage of EGFR 
by cetuximab has resulted in improved locoregional control and survival for patients 
with HNSCC [7] demonstrating that EGFR is a clinically relevant target for molecular 
therapies in addition to radiation.  
 
Tumour microenvironment 
Understanding the regulation of signalling pathways in tumours insensitive to 
particular treatment regimens will give information on tumour behaviour and can 
improve selection of patients for customised treatment options. A malignant tumour 
not only contains cancer cells but also exists of a variety of normal cell types that 
interact with each other and with a microenvironment that is characterised by both 
temporal and spatial heterogeneity. An imbalance between oxygen consumption and 
supply will result in (temporal) hypoxic tumour areas. Within the tumour 
microenvironment, hypoxia is relevant in almost all solid tumours. In our lab, research 
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regarding EGFR and tumour oxygenation is based on hypoxia measurements by 
pimonidazole staining [3,8,9]. Pimonidazole is a robust exogenous marker of hypoxia 
[10] and it only detects viable, hypoxic tumour cells, because a reduction step and 
binding are necessary for immunohistochemical detection. Several studies have 
proven the relevance and predictive value of pimonidazole [11-14]. Results from 
clinical trials with a treatment that counteracts enhanced tumour cell proliferation as 
well as hypoxia (Accelerated Radiotherapy with CarbOgen and Nicotinamide 
(ARCON)) show high locoregional control rates, in particular for oropharynx and 
larynx carcinoma patients with high pimonidazole binding levels [11,15].  
As described in this thesis, EGFR expression was predominantly found in better-
oxygenated tumour areas. Further, based on in vitro experiments, it is generally 
thought that EGFR and pAKT expression colocalize in the same tumour cells. However, 
it was surprising to find that in hypoxic areas AKT is activated without EGFR 
expression. This is a good example of the important role of the tumour 
microenvironment being responsible for the activation of the AKT protein, 
independent of EGFR. This indicates that the concept of EGFR-induced AKT activation 
is a simplification of a complex interaction between signal transduction pathways and 
the tumour microenvironment.  
Not only EGFR but also other receptors and mechanisms can activate AKT in more 
hypoxic areas. These include activation by other ErbB family members or receptor 
kinases like VEGFR [16], amplifications or mutations of the gene PIK3CA, 
amplifications of AKT itself or decreased expression of PTEN, a tumour suppressor 
[17-20]. On the other hand, (p)EGFR expression without pAKT expression as seen in 
some normoxic areas, indicates that not in all cells EGFR is actually activated or that 
EGFR activation necessarily leads to activation of the downstream PI3-K/AKT 
pathway. Apart from activation of AKT, EGFR can activate other cell survival pathways 
including mTOR and RAS/RAF/MAPK [16]. Therefore, future research should focus on 
these questions; how is AKT activated in hypoxic areas and can we target this 
activation upstream of AKT? And, apart from PI3-K/AKT, which EGFR-dependent 
pathways are mostly activated in normoxic areas and is there a link with radiotherapy 
resistance?  
 
Consequences for radiotherapy 
The amount of EGFR expression in a tumour is relevant for radiation response and is a 
prognostic factor after conventional fractionated radiotherapy [2] and surgery 
[21,22]. In the earlier 90’s two randomised trials showed that acceleration of 
radiotherapy schedules could improve patient outcome of high EGFR expressing 
tumours to the level of low EGFR expressing tumours, presumably by counteracting 
enhanced tumour cell proliferation [23,24]. In chapter 3 of this thesis we demonstrate 
that EGFR is predictive for the response to accelerated radiotherapy as well as for the 
response to hypoxia modification but in reverse ways: high EGFR expression levels 
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predict for good response to accelerated radiotherapy whereas low EGFR expression 
levels predict for good response to hypoxia modification.  
It is known that EGFR signalling is associated with the hypoxia response of tumour 
cells. Blocking EGFR can reduce intratumoural hypoxia by normalization of the 
irregular dysfunctional tumour vasculature, thereby improving perfusion and oxygen 
delivery [25-27] or by improved reoxygenation during fractionated radiotherapy [28]. 
A major pathway in the hypoxia response is the HIF-pathway. Under normoxic 
conditions HIF-1 is rapidly degraded, but under hypoxia it is stabilized [29-31]. 
Tumour cells with high pre-treatment EGFR expression levels might be better able to 
rapidly activate downstream survival pathways, resulting in activation of the HIF-
pathway, thereby thwarting the hypoxia modifying effect of ARCON. Possibly, 
therefore no advantage of this treatment was found for patients with high EGFR 
expressing tumours. In the latter, the role of EGFR inhibition in combination with 
hypoxia modification needs to be explored. By adding cetuximab, a monoclonal 
antibody against the EGF receptor, or erlotinib or gefitinib, EGFR tyrosine kinase 
inhibitors, EGFR signalling can be inhibited before treatment with ARCON. Combining 
these modalities for patients with high EGFR expressing tumours with high amount of 
hypoxic regions might be a next step forward in individualised treatment schedules 
leading to better survival for cancer patients. 
 
Different faces of AKT 
Anti-EGFR targeted therapy in combination with radiation has indeed shown to 
improve survival but only in a minor percentage of the patients (15% at best) [7]. New 
targets are tested for their usefulness as treatment options including AKT. Currently, 
the combination of radiotherapy with inhibitors of pAKT is under clinical 
investigation. Although the main known biological consequences of AKT activation are 
proliferation, growth, and tumour-induced angiogenesis, the prognostic significance of 
AKT activation in cancer is inconclusive. High pAKT expression has been associated 
with poor [32-35] and favourable prognosis [36-39] in different types of tumours. As 
presented in chapters 4 and 6 of this thesis, we found an association of low pAKT 
expression with increased regional metastatic risk in head and neck patients treated 
with radiotherapy. This raises the question if pAKT inhibition in head and neck cancer 
may actually promote a more metastatic phenotype and can lead to a worse clinical 
outcome. Three distinct genes encode for three isoforms of AKT. There are indications 
that these different isoforms have distinct functions in tumour progression depending 
on tumour type. Enhanced AKT1 signalling promotes tumour progression through 
increased cellular survival mechanisms, whereas AKT2 reportedly inhibits cancer 
growth [40-42]. AKT1 reduces while AKT2 enhances cell invasion and migration in 
breast and ovarian cancer [43,44]. Treatment with pAKT inhibitors, aimed at both 
isoforms together, might inhibit growth in some tumours, but could also induce a 
more pronounced metastatic behaviour in others. Unfortunately, we were not able to 
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perform AKT iso-form specific immunohistochemistry on our head and neck tumours, 
but in subsequent research this will be a major aim. The findings also highlight the 
necessity for isoform specific inhibitors and the importance of testing new molecular 
inhibitors for potential reverse outcome on different endpoints (local control versus 
metastases formation) before being introduced in the clinic. 
 
In this context it is noteworthy that in two independent cohorts of head and neck 
cancer patients, the second being a validation of the first study, we have found that 
low pAKT expression in primary tumours has a reverse correlation with lymph node 
metastases. Patients with negative lymph nodes had a significantly higher expression 
of pAKT compared to patients with positive lymph nodes. We hypothesized that low 
pAKT expression could lead to more migratory tumour cells through the process of 
epithelial to mesenchymal transition (EMT) [45]. In chapter 5 we showed that this 
EMT phenotype, characterized by reduced E-cadherin and upregulation of vimentin 
expression [46], is associated with a higher metastatic risk. In addition, when using a 
pAKT inhibitor laryngeal tumour cells reduced their E-cadherin expression and 
upregulated the expression of vimentin. With new techniques in our laboratory, e.g. 
migration and invasion assays, we now should be able to perform experiments 
thereby answering the question whether low pAKT and subsequently EMT leads to 
more metastases in our head and neck tumour models [47]. 
 
Another issue is whether lymph node metastases have the same expression levels of 
pAKT as the primary tumour. Is AKT only protecting tumour cells to undergo EMT and 
to migrate or does AKT maybe have a different role in tumour progression at the 
secondary sites? These questions are important for further understanding the 
influence of AKT in metastatic risk. Unfortunately, for the patients investigated in this 
thesis no tissue samples of the corresponding lymph nodes were available. In a new 
cohort of patients, biopsies of primary tumours and the corresponding metastatic 
lymph nodes will be collected, making it possible to further investigate these 
questions.  
 
Immunohistochemistry on biopsy material: strengths and limitations 
To demonstrate protein expression levels in biopsies of head and neck cancer 
patients, immunohistochemistry was used in this thesis. A major advantage of this 
method is that the amount of different proteins, their subcellular location and the 
expression relative to each other or to hypoxic areas and vessels with preservation of 
the tissue architecture can be investigated. In chapter 4 the co-expression of activated 
EGFR (pEGFR) and AKT (pAKT) is assessed relative to the vasculature. Although a 
positive correlation between total fraction pEGFR and pAKT was observed, levels of 
co-expression were low. Interestingly, the highest fractions of co-expression was close 
to the vessels, which again indicates that in head and neck tumours EGFR is only 
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partly responsible for activation of the PI3-K/AKT pathway. In more hypoxic areas 
AKT seems to be activated in an EGFR-independent manner. As these hypoxic tumour 
cells are able to activate proteins like AKT under harsh circumstances they may form 
an important subpopulation of the tumour responsible for tumour progression and 
treatment failure. Knowledge about the precise role and interaction of these proteins 
gives more insight in tumour cell behaviour and radioresistance.  
 
A point of concern is that biopsies were used which represents only part of the entire 
tumour. As a tumour is a heterogeneous interaction between cells and their 
environment, it is possible that valuable information is missed when taking a biopsy. 
This tumour heterogeneity was demonstrated in a study measuring proliferation in 
the centre and from the edge of an oesophageal carcinoma. There was a significant 
difference in proliferation index between these sites and this heterogeneity should be 
taken into account when using biopsy material [48]. 
To be able to identity thousands of genes and their expression patterns 
simultaneously, microarrays have been developed. Tumour response to radiotherapy 
might be predicted by identification of genes that are differentially expressed between 
radiosensitive and radioresistant tumours. Although these gene expression profilers 
can provide insights in genes involved in treatment failure, they are relatively 
expensive, difficult to interpret in a clinical setting, and statistics are complex. In 
addition, the microarrays provide no information about the expression pattern of the 
gene in relation to important microenvironmental features such as tumour cell 
hypoxia and vasculature. A combination of gene expression profiling and 
immunohistochemistry would be a valuable tool to gain more insight in which genes 
are involved in radioresistance [49,50] 
Characterisation of the whole tumour is possible with PET/CT or MRI techniques 
prior, during, and after treatment. On one side the tumour microenvironment can be 
imaged, such as tumour cell proliferation using 3’-deoxy-3’-18-F-fluorothymidine 
(18FLT) or tumour cell hypoxia using 18-F-fluoromisonidazole (18FMISO) but also 
signal transduction pathways can been visualised. Radionuclide labelled monoclonal 
antibodies directed against the EGFR might in the future be used to select patients for 
EGFR-targeted therapies, although more clinical trials are necessary to further explore 
this [51,52]. Although these techniques have the great advantage that a tumour can be 
monitored during treatment, they cannot distinguish in which cellular (sub-) 
compartment proteins are being expressed neither can co-expression of different 
markers be investigated. Possibly, early tumour characterisation by 
immunohistochemistry supplemented with PET/CT-imaging during treatment can 
provide an important tool for adaptation and optimisation of treatment plans. 
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Final remark 
The results of this thesis make clear that the tumour microenvironment is of major 
influence on the response of tumours to treatment. Tumour progression is complex 
and difficult to understand. The more factors we unravel that are involved in this 
process the more new questions are raised. The tumour microenvironment is 
involved in activation of EGFR-driven signalling pathways as well as EGFR-
independent activation of proteins such as AKT. The exact mechanisms and elements 
of the microenvironment that drive EGFR toward PI3-K/AKT signalling remain 
unclear. The work presented in this thesis describes only details of a complex picture 
in which EGFR and pAKT are involved not only in a cancer-type specific manner, but 
also in a patient-tumour-specific way. It highlights the complex interaction and 
variation of tumours of the same clinical location or stage and necessity for 
individualised treatment regimes. With the ability to select patients based on tumour 
characteristics such as hypoxia, we are now able to treat only those patients likely to 
benefit from hypoxia modifying treatment modalities. Identification and targeting of 
key molecules of signal transduction pathways in addition to modulation of the 
tumour microenvironment could further improve the possibility of individualised 
treatment regimes for the best quality of care while minimizing toxicity levels. 
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Summary 
The tumour microenvironment plays a key role in the treatment response of 
solid tumours. The central aim of this thesis was to investigate the activation of the 
EGFR-PI3-K/AKT pathway in biopsies of patients with head and neck cancer and its 
implication for radiation resistance. Besides the potential prognostic or predictive 
value, we evaluated expression of key molecules of this pathway in relation to 
microenvironmental factors, such as vasculature and hypoxia.   
In chapter 2 we discussed the interaction of the EGFR-PI3-K/AKT pathway 
with the tumour microenvironment and its implications for radiation treatment. The 
current status of knowledge is reviewed and suggestions for future research are given. 
Treatment failure through radioresistance of various tumour types is associated with 
activation of the epidermal growth factor receptor (EGFR). Tumour cell proliferation, 
DNA-repair, hypoxia, and metastases formation are mechanisms in which EGFR 
signalling is assumed to have an important role. In clinical trials, a correlation has 
been demonstrated between high EGFR expression in tumours and poor outcome 
after radiotherapy. Inhibition of EGFR signalling pathways improves the effectiveness 
of radiotherapy in solid tumours, like head and neck cancers, by overcoming these 
main mechanisms of radioresistance. The fact that only a minority of the patients 
respond to EGFR inhibitors reflects the complexity of interactions between EGFR-
dependent signalling pathways and the tumour microenvironment.  
In chapter 3 the purpose was to investigate if EGFR expression levels are 
associated with response to ARCON in patients with laryngeal carcinoma. Accelerated 
radiotherapy (AR) improves the poor outcome associated with EGFR overexpression 
in head and neck cancers. Combining AR with carbogen and nicotinamide (ARCON) 
counteracts enhanced tumour cell proliferation- and hypoxia-related radioresistance. 
Paraffin-embedded biopsies of 272 patients randomized between AR and ARCON 
were processed for immunohistochemical staining of EGFR. A large variation was 
observed in EGFR fractions between tumours with expression levels ranging from 0-
0.93 (median fraction 0.4). No difference in 5-year locoregional control was found 
between low and high EGFR expressing tumours in the AR arm (69% versus 75%), 
which is in line with the established effect of AR in EGFR overexpressing tumours. 
There was, however,  a significant association in the ARCON arm: patients with low 
EGFR levels had a better 5-year locoregional control (88% versus 72% p=0.02) and 
disease-specific survival (92% versus 77% p=0.01). ARCON improved locoregional 
control relative to AR only in patients with low EGFR expression (HR 0.34 p=0.009). It 
is to conclude that EGFR is a predictive biomarker for the selection of patients that 
will or will not respond to ARCON. 
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In chapter 4 the contribution of activated p(hosphorylated)EGFR and its 
downstream signalling via PI3-K/AKT was investigated. pEGFR, pAKT, hypoxia (by 
means of pimonidazole staining), and vessels were visualised. It was hypothesised 
that hypoxic tumour cells with an activated EGFR-PI3-K/AKT pathway could have a 
survival advantage after treatment with radiotherapy. Both pEGFR (median 0.6%, 
range 0-34%) and pAKT (median 1.8%, range 0-16%) expression differed between 
tumours. A significant correlation between pEGFR and pAKT (rs 0.44, p=0.004) was 
seen, however, image analysis revealed that this was not always based on spatial 
coexpression. The correlation between expression of pEGFR and pAKT is indicative of 
activation of the PI3-K/AKT pathway through phosphorylation of EGFR. Since not all 
tumours show coexpression to the same extent, other membrane receptors must be 
involved in the activation of this pathway as well. Un expected and somewhat 
counterintuitive finding was that low pAKT expression was associated with increased 
risk of regional recurrence (p<0.05) and distant metastasis (p=0.04). This 
phenomenon is further investigated in chapter 6.  
Chapter 5 focused on the expression of markers involved in epithelial-
mesenchymal transition which is required for metastasis formation; E-cadherin and 
vimentin. E-cadherin is a transmembrane glycoprotein involved in cell-cell adhesion 
while vimentin is highly expressed in mesenchymal cells. Vimentin is positively 
correlated with increased metastasis. In this chapter tumour biopsies of 26 head and 
neck cancer patients were immunohistochemically stained for E-cadherin and 
vimentin. We found a large variation in E-cadherin (median 17%, range 0-51%) and 
vimentin (median 0%, range 0-20%) expression between tumours. Tumours with low 
E-cadherin expression showed a significantly higher incidence of metastasis 
formation compared to tumours with high expression (81% versus 19%, p=0.004). 
Enhanced expression of vimentin was associated with a trend towards a higher 
metastatic risk (33% versus 77%) compared to tumours without expression of 
vimentin. All patients with low E-cadherin and high vimentin expression (an EMT-
phenotype) developed distant metastasis versus only 44% of the other patients 
(p=0.008). These data indicate that loss of E-cadherin and gain of vimentin may be 
associated with enhanced migration of tumour cells, leading to higher metastatic risk 
of head and neck cancer patients.  
Chapter 6 aggregated the EGFR-PI3-K/AKT pathway with E-cadherin and 
vimentin expression data. Targeting AKT is considered as a treatment option for 
several solid tumour types. However, in chapter 4 we showed that low pAKT 
expression in the primary tumour was associated with lymph node metastasis. Our 
aim in chapter 6 was to validate this finding in an independent cohort of laryngeal 
cancer patients and to examine the effect of pAKT inhibition on EMT of laryngeal 
cancer cells. We visualised EGFR, pAKT, vimentin, E-cadherin, hypoxia, and blood 
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vessels in biopsy material of 78 patients. In six laryngeal cancer cell lines E-cadherin 
and vimentin mRNA and protein expression was quantified by respectively real-time 
polymerase chain reaction (q-pcr) and by immunohistochemistry before and after 
treatment with the pAKT inhibitor MK-2206. We found a significant correlation 
between low pAKT in the primary tumour and positive lymph node status (p=0.0005). 
Tumours with lymph node metastases had approximately 10-fold lower median pAKT 
values compared to tumours without lymph node metastases, validating our previous 
findings. After inhibition of pAKT in laryngeal cancer cells with MK-2206 upregulation 
of vimentin and a downregulation of E-cadherin occurred, consistent with EMT 
induction predisposing for an increased metastatic risk. These results describe a 
complex picture in which pAKT inhibition should be considered in a cancer-type 
specific manner. We recommend that new pAKT inhibitors should be tested for 
potential stimulation of EMT and be introduced in the clinic prudently.  
Finally, chapter 7 provides a general discussion of findings presented in this 
thesis and future considerations are highlighted. 
Summary 
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Samenvatting  
Het doel van dit proefschrift was om de functie van de EGFR-PI3-K/AKT 
signaleringsroute te onderzoeken in biopten van patiënten met hoofd-halstumoren en 
te testen welke rol deze speelt bij resistentie tegen radiotherapie. Naast het bepalen 
van de mogelijke prognostische en predictieve (voorspellende) waarde van EGFR in 
deze patiënten werd ook de expressie van EGFR en pAKT in te tumor gerelateerd aan 
factoren binnen het tumor-micromilieu, zoals hypoxie (zuurstofgebrek) en de 
verdeling van de bloedvaten.  
 
Hoofdstuk 1 geeft een introductie over hoofd-halstumoren, radioresistentie 
en de EGFR-PI3-K/AKT signaleringsroute. Onderstaande is een korte samenvatting 
van dit hoofdstuk.  
 
Hoofd-halstumoren 
Hoofd-halskanker behoort tot de tien meest voorkomende tumor-soorten met 
een incidentie van ongeveer 2400 patiënten per jaar in Nederland. Hoofd-
halstumoren zijn meestal afkomstig van het slijmvlies van de larynx, farynx en neus- 
en mondholte. De belangrijkste oorzaken van het krijgen van hoofd-halstumoren zijn 
roken en overmatig alcoholgebruik. Een infectie met het humaan papillomavirus 
(HPV) is in toenemende mate verantwoordelijk voor het ontstaan van orofarynx-
tumoren bij relatief jonge, niet rokende patiënten. De initiële klachten zijn meestal 
niet-specifiek zoals keelpijn en daardoor presenteren de meeste patiënten zich met 
vrij grote tumoren die vaak al metastasen (uitzaaiingen) in de lymfeklieren van de 
hals vertonen. Doordat chirurgie in het hoofd-halsgebied vaak tot belangrijk 
functieverlies leidt is de voorkeursbehandeling voor deze tumoren radiotherapie; 
deze therapie is effectief in een vroeg stadium van de ziekte maar minder in 
vergevorderd stadia en slechts palliatief (niet gericht op genezing) bij tumoren met 
metastasen op afstand. In de afgelopen jaren is er veel onderzoek gedaan naar het 
optimaliseren van behandelingsmethoden om de kans op overleving te vergroten. 
Voorbeelden hiervan zijn het versnellen (accelereren) van radiotherapie schema’s of 
het combineren van radiotherapie met chemotherapie of medicijnen die ingrijpen op 
moleculaire doelen in de tumorcel. Een beperkt deel van de patiënten (ongeveer 15%) 
heeft voordeel van deze behandelingen maar helaas ondervindt iedereen de 
bijwerkingen ervan. Het is dus noodzakelijk om patiënten voor de juiste behandeling 
beter te kunnen selecteren. 
 
Mechanismen betrokken bij radioresistentie 
 Het tumor-micromilieu speelt een belangrijke rol bij de uitkomst van 
radiotherapie. Hoe goed tumorcellen reageren op de behandeling hangt af van de 
tumoreigen gevoeligheid voor bestraling (intrinsieke radiosensitiviteit), de snelheid 
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van deling (proliferatie), zuurstofgebrek (hypoxie) en de mogelijkheid tot 
metastasering. Intrinsieke radiosensitiviteit wordt bepaald door de mate waarin 
tumorcellen de bestralingsschade aan het DNA kunnen herstellen. Versnelde 
proliferatie treedt op doordat tumorcellen reageren door naarmate de behandeling 
vordert actiever te gaan delen. Dit kan tegengegaan worden door radiotherapie in een 
kortere periode, geaccelereerd, te geven. Hypoxie komt voor in bijna alle hoofd-
halstumoren. Acute hypoxie ontstaat door een willekeurige en kortdurende sluiting 
van de slecht gevormde tumor bloedvaten terwijl chronische hypoxie het gevolg is van 
een te grote afstand van de tumorcel naar het dichtstbijzijnde bloedvat. Zoals te zien is 
in figuur 1 van hoofdstuk 1 kunnen beide vormen van hypoxie in dezelfde tumor 
voorkomen en is het gevolg dat er een tekort aan zuurstof en voedingsstoffen in de 
tumorcel optreedt. Zuurstof is essentieel voor het effect van bestraling omdat het 
fungeert als intermediair bij het ontstaan van DNA schade. Indirect kan hypoxie leiden 
tot activatie van genen en eiwitten die verantwoordelijk zijn voor tumor progressie of 
metastasering en uiteindelijk tot een slechtere prognose van de patiënt. Bij 
metastasering ondergaan tumorcellen veranderingen waarbij ze los komen van de 
primaire tumor, kunnen gaan zwerven in de bloed- of lymfebaan en opnieuw kunnen 
gaan hechten op een tweede lokalisatie in het lichaam. Voor die eerste stap is een 
proces genaamd epitheliale-mesenchymale transitie (EMT) noodzakelijk. Hierbij 
veranderen de tumorcellen van een hechtende, epitheliale cel in een mesenchymale 
cel. Metastasen hebben een zeer grote impact op de prognose van de patiënt en 
daarom is het erg belangrijk om deze mechanismen te begrijpen. 
 
EGFR-PI3-K/AKT signaleringsroute 
 EGFR is een eiwit dat zich op het membraan van de tumorcel bevindt en in 
hoofd-hals-kanker in grote mate tot expressie komt. Zoals figuur 2 in hoofdstuk 1 laat 
zien, kan activatie van EGFR leiden tot activatie van verschillende signaleringsroutes 
in de tumorcel, waaronder de PI3-K/AKT route. Deze signaleringsroute is belangrijk 
voor de respons op radiotherapie doordat het een groot aantal cellulaire functies 
reguleert, waaronder de mogelijkheid tot proliferatie, DNA-herstel en metastasering. 
Uit eerder onderzoek is al gebleken dat EGFR een voorspellende waarde heeft in 
solide tumoren, waarbij er een sterke correlatie is aangetoond tussen een hoge EGFR 
expressie in de tumor en een slechtere prognose voor de patiënt. Een klinische studie 
heeft laten zien dat toevoeging van een therapie gericht op het remmen van EGFR 
signalering (met behulp van het geneesmiddel cetuximab) aan radiotherapie leidt tot 
een verbeterde locoregionale controle bij patiënten met hoofd-halstumoren 
vergeleken met de patiënten die alleen bestraald werden. Helaas blijkt die niet voor 
alle patiënten te werken, terwijl zij wel allemaal aan deze intensievere behandeling en 
bijwerkingen worden blootgesteld. Het is in de laatste jaren duidelijk geworden dat 
het tumor-micromilieu een grote rol speelt in EGFR signalering en activatie van de 
PI3-K/AKT route. In dezelfde tumor zijn er tumorcellen met actief EGFR terwijl ze 
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geen actief AKT bezitten, maar ook delen waren AKT actief is zonder dat er EGFR 
aanwezig is. Hieruit blijkt dat het erop lijkt dat de activatie van AKT niet altijd door 
EGFR plaatsvindt maar er ook andere factoren een rol spelen. Dit geeft aan dat de 
interactie tussen het tumor-micromilieu en EGFR signaleringsroutes complex is.   
 
In hoofdstuk 2 wordt de interactie tussen de tumor en zijn micromilieu 
besproken en wat dit voor gevolgen heeft voor radiotherapie. Er wordt een overzicht 
gegeven van de huidige stand van zaken en aanbevelingen gegeven voor toekomstig 
onderzoek. Het falen van een behandeling door ongevoeligheid van tumoren voor 
bestraling is geassocieerd met activatie van EGFR. Tumorcelproliferatie, herstellen 
van DNA-schade, hypoxie en metastasering zijn vier mechanismen waarbij 
signaleringsroutes via EGFR een belangrijke rol in spelen. In klinische trials is een 
correlatie aangetoond tussen een hoge expressie van EGFR in tumoren en een slechte 
overleving van de patiënt na radiotherapie. Het blokkeren van deze EGFR 
signaleringsroutes in de tumor verbetert de effectiviteit van radiotherapie in solide 
tumoren, waaronder hoofd-halstumoren. Dat de interactie tussen EGFR afhankelijke 
signaleringsroutes in tumoren en het tumor micromilieu complex is blijkt uit het feit 
maar een klein deel van de patiënten (maximaal 15%) met een hoge EGFR expressie 
baat heeft bij behandeling met deze EGFR-remmers.  
 
Het doel van hoofdstuk 3 was te onderzoeken of expressie van EGFR 
geassocieerd is met de respons van patiënten met larynxtumoren op behandeling met 
ARCON: geaccelereerde radiotherapie (AR) met carbogeen en nicotinamide (CON). AR 
verbetert de slechte prognose die gerelateerd is aan overexpressie van EGFR in hoofd-
halstumoren. Door het geven van ARCON wordt zowel versnelde tumorcelproliferatie 
als hypoxie-gerelateerde radioresistentie tegengegaan. Paraffine coupes van 272 
patiënten die gerandomiseerd waren tussen behandeling met AR of ARCON werden 
immunohistochemisch gekleurd voor EGFR. Door middel van analyses met 
automatische beeldverwerking werden fracties EGFR bepaald: de hoeveelheid EGFR 
positieve tumorcellen gedeeld door het totaal aantal tumorcellen. Een grote variatie 
werd gevonden tussen de verschillende tumoren met EGFR fracties tussen 0 en 0,93 
(mediane fractie 0,4). Er was geen significant verschil tussen hoge en lage EGFR 
expressie in de 5-jaars locoregionale controle in de patiënten behandeld met AR alleen 
(69% versus 75%). Dit komt overeen met eerdere studies die aantonen dat het 
accelereren van radiotherapie schema’s de prognose van tumoren met hoge EGFR 
expressie verbeteren tot dezelfde prognose van tumoren met lage EGFR expressie. 
Wel was er een significante correlatie in de patiënten die behandeld waren met 
ARCON: patiënten met een lage EGFR fractie hadden een betere 5-jaars locoregionale 
controle dan degenen met een hoge EGFR fractie (88% versus 72%, p=0,02) en ook 
ziektevrije overleving (92% versus 77%, p=0,01). Behandeling met ARCON verbeterde 
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de locoregionale controle ten opzichte van behandeling met AR alleen voor patiënten 
met een lage EGFR expressie (HR 0,34 p=0,009). Uit dit onderzoek blijkt dat EGFR 
expressie een predictieve biomarker is om te voorspellen of patiënten wel of geen 
baat zullen hebben bij behandeling met ARCON.  
 
In hoofdstuk 4 wordt de geactiveerde vorm van EGFR, gefosforyleerd 
(p)EGFR, en de signaleringsroute PI3-K/AKT nader onderzocht. Hypoxische tumoren 
die de EGFR-PI3-K/AKT signaleringsroute kunnen activeren hebben mogelijk een 
overlevingsvoordeel na behandeling met radiotherapie. Ingevroren biopten van 
verschillende hoofd-halstumoren werden gekleurd middels immunofluorescentie 
voor pEGFR, pAKT, hypoxie en bloedvaten, en fracties werden bepaald. Zowel pEGFR 
(mediaan 0,6%, min-max 0-34%) en pAKT (mediaan 1,8%, min-max 0-16%) expressie 
varieerde sterk tussen tumoren. Er was een significante correlatie tussen pEGFR en 
pAKT (rs 0.44, p=0.004), maar dit bleek niet altijd gebaseerd op activatie van beide 
eiwitten in dezelfde tumorcel. Een lage expressie van pAKT was geassocieerd met 
lymfeklier metastasen op het moment van diagnose (0.5%  resp. 5.8% p=0.001). Lage 
pAKT expressie lijkt ook  te leiden tot een verhoogd risico op zowel regionale 
terugkeer van de ziekte (p<0.05) als metastasen op afstand (p=0.04). De correlatie 
tussen pEGFR en pAKT expressie in tumoren zou erop kunnen duiden dat activatie 
van de PI3-K/AKT signaleringsroute door middel van activatie van EGFR tot stand 
komt. Echter, aangezien niet altijd pEGFR en pAKT in dezelfde tumorcel tot expressie 
komt moeten er andere factoren, bijvoorbeeld andere signaleringsroutes of mutaties 
in de tumor, een rol spelen bij activering van AKT.  
 
Hoofdstuk 5 richt zich op de expressie van de markers E-cadherine en 
vimentine die een rol spelen bij epitheliale-mesenchymale transitie (EMT), een proces 
dat nodig is voor tumorcellen om te kunnen metastaseren. E-cadherine is een eiwit 
dat zich op het membraan van een cel bevindt en een rol speelt bij cel-cel contact en 
aanhechting. Vimentine komt in mesenchymale cellen tot expressie en correleert in 
eerdere onderzoeken met verhoogde kans op metastasering van tumoren. Voor dit 
onderzoek werden biopten van 26 patiënten gekleurd voor E-cadherine en vimentine 
en werden fracties bepaald. Er bestond een grote variatie tussen de tumoren voor 
zowel de expressie van E-cadherine (mediaan 17%, min-max 0-51%) als van 
vimentine (mediaan 0%, min-max 0-20%). Patiënten met tumoren met een lage 
fractie E-cadherine hadden significant meer metastasen vergeleken met tumoren die 
een hoge E-cadherine fractie hadden (81% versus 19%, p=0.004). Een verhoogde 
expressie van vimentine was geassocieerd met een trend op een hoger risico op 
metastasen (33% versus 77%). Alle patiënten met zowel een lage E-cadherine als een 
hoge vimentine expressie in de tumor (zoals gezien bij het proces van EMT) kregen 
afstandsmetastasen vergeleken met slechts 44% van de overige patiënten. Deze data 
tonen aan dat het verlies van E-cadherine gecombineerd met een verhoogde expressie 
118 
 
van vimentine in tumoren geassocieerd is met een versterkte migratie van 
tumorcellen en uiteindelijk tot een verhoogd risico op de vorming van metastasen bij 
hoofd-hals kanker kan leiden.  
  
In hoofdstuk 6 worden de twee voorgaande hoofdstukken samengebracht; 
de EGFR-PI3-K/AKT signaleringsroute en de EMT-markers E-cadherine en vimentine. 
Therapieën die als doel hebben om AKT te verminderen en hierdoor de prognose van 
de patiënt te verbeteren zijn tegenwoordig een behandelingsoptie voor verschillende 
solide tumoren. In hoofdstuk 4 van dit proefschrift werd aangetoond dat een lage 
pAKT expressie in de tumor geassocieerd is met lymfekliermetastasen In dit 
hoofdstuk is het doel om deze bevinding te valideren in een apart cohort van 
patiënten met uitsluitend larynxtumoren. Tevens werd het effect van pAKT remming 
op EMT in cellijnen van larynxkanker bestudeerd. In biopten van 78 patiënten werden 
EGFR, pAKT, E-cadherine, vimentine, hypoxie en bloedvaten gekleurd. Daarnaast werd 
in 6 cellijnen de mRNA expressie van E-cadherine en vimentine bepaald door middel 
van een kwantitatieve polymerase kettingreactie (q-pcr) en de expressie van de 
eiwitten  met immunohistochemische kleuringen voor en na behandeling van deze 
cellen met de pAKT remmer MK-2206. Bevestigd werden onze onverwachte 
resultaten uit hoofdstuk 4, dat een lage expressie van pAKT in tumoren gecorreleerd 
is met lymfeklier metastasen (p=0.005). Tumoren met lymfekliermetastasen hadden 
ongeveer een 10 maal lagere hoeveelheid pAKT vergeleken met tumoren zonder 
lymfekliermetastasen. Na remming van pAKT in larynxkankercelllijnen met MK-2206 
werd een verlaging gezien van E-cadherine expressie en een verhoogde vimentine 
expressie, consistent met inductie van EMT en daardoor duidend op een verhoogd 
risico op metastasevorming. Op basis van deze bevindingen wordt aanbevolen dat, 
voor introductie in de kliniek, nieuwe pAKT remmers getest zouden moeten worden 
op mogelijke stimulatie van EMT in hoofd-halskanker.  
  
Tenslotte wordt in hoofdstuk 7 de resultaten van alle hoofdstukken in een 
breder perspectief besproken en worden er suggesties voor toekomstig onderzoek 
gegeven. De resultaten van dit proefschrift maken duidelijk dat het tumor micromilieu 
een grote invloed heeft op de respons van tumoren op de gekozen behandeling. De 
progressie van tumoren is een complex en moeilijk te doorgronden proces. Bij elke 
nieuwe ontdekking komen nieuwe vragen naar boven. Het tumor micromilieu is zowel 
betrokken bij de activatie van EGFR gestuurde signaleringsroutes als bij de activatie 
van EGFR onafhankelijke eiwitten zoals AKT. Welke mechanismes en elementen van 
dit tumor micromilieu leiden tot activatie van de EGFR-PI3-K/AKT signaleringsroute 
blijft echter onduidelijk. Het werk beschreven in dit proefschrift zijn slechts details 
van een complex geheel waarbij EGFR en pAKT betrokken zijn, zowel in een tumor-
type (namelijk hoofd-halskanker) als patiënt-tumor specifieke manier. De variatie 
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tussen tumoren die tot dezelfde klinische locatie of stadium behoren maken duidelijk 
dat het noodzakelijk is patiënten geïndividualiseerd te kunnen behandelen. Met de 
mogelijkheid om patiënten te selecteren op basis van tumor specifieke kenmerken, 
zoals hypoxie, zijn we in staat om alleen die patiënten te behandelen die baat hebben 
bij zogenoemde hypoxie modificerende therapieën. De identificatie van belangrijke 
signaleringsroutes kan leiden tot de ontwikkeling van therapieën die specifiek op 
gericht zijn op tumor specifieke eigenschappen. Het combineren van deze 
verschillende therapieën kan bijdragen aan de mogelijkheid tot geïndividualiseerde 
behandelingsstrategieën zodat het mogelijk wordt om te kiezen voor de meest 
geschikte behandeling met de laagste toxiciteit en de beste kwaliteit van leven.  
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Dankwoord  
 
Het laatste hoofdstuk…het enige hoofdstuk in mijn proefschrift wat niet geschreven, 
gecorrigeerd, geschrapt, herschreven, gereviseerd en becommentarieerd is. En dat 
terwijl dit waarschijnlijk het meest gelezen hoofdstuk zal zijn. Ik wil iedereen 
bedanken die de afgelopen jaren mij geholpen heeft dit proefschrift voor elkaar te 
krijgen; iedereen die inhoudelijke input gegeven heeft, maar ook zeker diegene die 
een voor luisterend oor zorgden en die er waren om te sporten en ontspannen. Zonder 
deze combinatie had ik het nooit volbracht!  
 
Een aantal mensen wil ik in het bijzonder bedanken: 
 
Professor Kaanders, beste Hans, jij gaf mij de kans en vertrouwen om aan 
mijn promotie te beginnen. In de afgelopen jaren heb ik veel van je geleerd, je ervaring 
als radiotherapeut, onderzoeker én schrijver hebben ervoor gezorgd dat het gelukt is 
om mijn manuscript af te ronden waarvan alle artikelen gepubliceerd zijn. 
 
Professor van de Kogel, beste Bert, jouw kritische blik en vragen maakte dat 
ik nooit meer een presentatie wil geven zonder deze tot in de puntjes voor te 
bereiden. Ik weet zeker dat ik mijn eerste Klaas Breur Reisbeurs zonder jouw 
opmerkingen tijdens de oefenpresentatie nooit had gewonnen. Jouw knik en 
opgestoken duim tijdens ESTRO presentaties gaven mij ontzettend veel vertrouwen, 
grote dank daarvoor.  
 
Dr. Bussink, beste Jan, radiotherapeut, onderzoeker en hoofd van onze lab-
groep, ik vind het bewonderingswaardig! Jouw enthousiasme voor wetenschappelijk 
onderzoek werkt aanstekelijk en tijdens overleggen werden problemen moeiteloos 
door jou in oplossingen en ideeën omgezet. Bedankt dat je deur altijd openstond.  
 
Dr. Span, beste Paul, jouw moleculaire kennis en het nieuwe lab maakte dat 
mijn onderzoek nog veelzijdiger kon worden; van patiënten data terug naar cellen en 
door naar muizen experimenten. Het enthousiasme dat je hebt voor statistische 
uitdagingen en nieuw verworven resultaten zorgde ervoor dat er veel nieuwe ideeën 
ontstonden. Helaas is niet alles bruikbaar geweest voor dit proefschrift maar het heeft 
mijn promotietraject zeker uitdagender gemaakt.  
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Jasper, Hans, Marieke en Wenny, de analisten van het lab. Bedankt voor alle 
uren waarin ik gebruik mocht maken van jullie expertise.  
Jasper, mijn proefschrift had hier niet gelegen zonder jouw hulp. Alle 
‘immunoplaatjes’ die ik zelf creëerde konden eigenlijk niet tippen aan die van jou en 
daar is mijn mooie kaft het bewijs van! Bedankt dat je mijn paranimf bent vandaag en 
ik tot op het allerlaatste moment gebruik mag maken van je hulp! 
 
Anika, Hanneke, Laura, Marloes en Tineke, samen hebben we niet alleen een 
kamer, een lab en experimenten maar ook vele frustraties, spanningen en blije 
momenten gedeeld de afgelopen jaren. Zonder jullie zou het een stuk minder leuk 
geweest zijn op kamer 18. Heel veel succes bij het afronden van jullie promoties en in 
jullie verdere carrières.  
 
Paul, jouw analyses zijn de basis van mijn gehele onderzoek! Bedankt voor je 
rustige uitleg als ik iets niet begreep. Bianca, Esther, Ilse en Saskia, bedankt voor jullie 
hulp wanneer ik moeilijke vragen had of gewoon een praatje wou maken.  
 
Iedereen van de afdeling Radiotherapie bedankt! Nieuwjaarsfeesten, dagjes-
uit, weekendje skiën, praatjes in de koffiekamer, koffie in de klifio-kamer; ik heb er 
van genoten!  
Daan, ondanks dat onze specifieke interesse binnen de radiotherapie nogal 
ver uit elkaar ligt, bleken onze privé interesses meer overeen te komen. Je hebt mij er 
af en toe echt doorheen gesleept, dank je! 
 
Mijn oude collega’s (Bureau GMV) voor het gevoel dat ik hieraan kon 
beginnen. Ad, Loes en Petra; we kunnen het onderwerp afronden promotie nu 
afstrepen en nieuwe onderwerpen aansnijden tijdens onze wandel/fietsmiddagen! 
Mijn nieuwe collega’s (RIVM VSP) voor het vertrouwen dat ik dit tot een goed einde 
zou brengen. Wanneer telkens gevraagd word hoe het ermee staat (lees: feest?) kon ik 
niet anders dan het afmaken!  
 
Vrienden maken de vrouw! Lieve allemaal, ik ben er van overtuigd dat ik hier 
niet had gestaan zonder jullie!  
Anouk, Inge, Linda, Maaike, Miranda, Miranda, Monique, Sandra en Wendy; 
bedankt voor alle ontspanning, leuke weekendjes weg, high tea’s, en borrelavondjes! 
Ondanks de afstand zijn jullie altijd dichtbij gebleven. Er zal zeker goed geproost en 
gefeest worden om dit te vieren.  
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Bart, Dinant, Jeanette, Joost, Laura, Martijn, Melissa, Milou, Olaf, Peter, Peter, 
Remco, Rob, Sander en Sandra; zoveel (studie)jaren al vrienden, zoveel mooie 
herinneringen! Ik hoop dat we nog veel meer nieuwe herinneringen zullen creëren. 
Jullie hebben mij door vele momenten heen gesleept! Wat is het gaaf om 
studie/werk/bier/sport-uitdagingen, hoogte- en dieptepunten te mogen delen met 
jullie!  
Sander, je weet niet half hoeveel ik aan jou gehad heb tijdens onze (HLO en 
BMW) studies en ik vind het een onmeunig grote eer dat je vandaag naast mij wilt 
staan als paranimf! Remco, zonder jouw vertrouwen dat mijn studie- en werkkeuzes 
de juiste waren had dit proefschrift hier niet gelegen. Bedankt dat je dat mogelijk 
maakte en mij daarin altijd gesteund hebt!  
 
Pap en Mam, ik ben ontzettend dankbaar voor alle mogelijkheden die jullie 
mij geboden hebben. Vele wegen leiden naar Rome en ik heb daarvan de meeste wel 
bewandeld. Jullie stonden achter mijn keuzes die vast niet altijd even duidelijk waren. 
Bedankt dat ik dit alles waar heb mogen maken.  
Remco, mijn kleine broertje, het zonnetje in huis! Door jou heb ik geleerd dat 
het leven geleefd moet worden en ik alle kansen moet grijpen die er zijn. Het is nu tijd 
voor een feestje! 
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Monique Maria Nijkamp werd geboren op 6 augustus 1981 te Harderwijk. Zij groeide 
op in Harderwijk en Dronten en kwam uiteindelijk in het Twents Losser terecht. Van 
1993 tot 1998 volgde zij de HAVO aan het Twents Carmellyceum te Oldenzaal. Na een 
kort uitstapje op de pabo begon zij in 1999 met de opleiding Hoger Laboratorium 
Onderwijs aan de Saxion Hogescholen te Enschede met Medische Microbiologie als 
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